

RADIOLOGICAL AND NUCLEAR COUNTERMEASURES PROGRAM

Securing America against unconventional attacks

UCRL-TR-215887

Technology Assessment and Roadmap for the Emergency Radiation Dose Assessment Program ERDAP



HOMELAND SECURITY
SCIENCE AND TECHNOLOGY

Report Documentation Page				Form Approved OMB No. 0704-0188	
Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to a penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.					
1. REPORT DATE JUN 2005		2. REPORT TYPE		3. DATES COVERED 00-00-2005 to 00-00-2005	
4. TITLE AND SUBTITLE Technology Assessment and Roadmap for the Emergency Radiation Dose Assessment Program (ERDAP)				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S)				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of California, Lawrence Livermore National Lab, Livermore, CA, 94551				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release; distribution unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT					
15. SUBJECT TERMS					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT Same as Report (SAR)	18. NUMBER OF PAGES 36	19a. NAME OF RESPONSIBLE PERSON
a. REPORT unclassified	b. ABSTRACT unclassified	c. THIS PAGE unclassified			

Technology Assessment and Roadmap for the Emergency Radiation Dose Assessment Program **ERDAP**

Acknowledgment

The U.S. Department of Homeland Security (DHS) is acknowledged as the sponsor of this work, under DHS contract # HSHQPB05X00035, a "work for others" arrangement, issued under the prime contract for research, development, test, and evaluation services between the U.S. Department of Energy and the Regents of the University of California as operator of the Lawrence Livermore National Laboratory (LLNL). The U.S. Government is granted for itself and others acting on its behalf a paid-up, nonexclusive, irrevocable worldwide license to content authored by LLNL to reproduce, prepare derivative works, distribute copies to the public, and perform publicly and display publicly, by or on behalf of the Government. All other rights are reserved by LLNL.

DISCLAIMER

This document was prepared as an account of work sponsored by an agency of the United States Government. Neither the United States Government nor the University of California nor any of their employees makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or the University of California. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government or the University of California and shall not be used for advertising or product endorsement purposes.

This work was performed under the auspices of the U.S. Department of Energy by the University of California, Lawrence Livermore National Laboratory under Contract No. W-7405-Eng-48.

June 2005

UCRL-TR-215887

CONTENTS

1 Executive Summary

3 Technology Summary

5 What Should be Done:

Roadmap for a National Program in Emergency Radiation Dose Assessment

7 Supporting Information

A. **Context for the Use of Radiation Injury Assessment Tools**

1. Event Characteristics and Diagnostic Requirements
2. Triage and Initiation of Treatment
3. Diagnostic Requirements for Sensitivity, Accuracy, Throughput and Turnaround Time

10 B. **Current Methods and Tools for Triage and Emergency Dose Assessment**

1. Biological and Clinical Signatures of Radiation Dose Assessment
2. Dosimetry and Location-Based Assessment
3. Measurement of Radioisotope Contamination
4. Pre-Positioned Physical Dosimeters

15 C. **Assessment of Emerging Dosimetry Technologies**

1. Biological Measurements
2. Physico-Chemical Measurements

22 References

30 Appendix A.

Joint Interagency Working Group Participants

31 Appendix B.

List of Abbreviations





Executive Summary

A Joint Interagency Working Group (JIWG) under the auspices of the Department of Homeland Security Office of Research and Development conducted a technology assessment of emergency radiological dose assessment capabilities as part of the overall need for rapid emergency medical response in the event of a radiological terrorist event in the United States. The goal of the evaluation is to identify gaps and recommend general research and development needs to better prepare the Country for mitigating the effects of such an event. Given the capabilities and roles for responding to a radiological event extend across many agencies, a consensus of gaps and suggested development plans was a major goal of this evaluation and road-mapping effort. The working group consisted of experts representing the Departments of Homeland Security, Health and Human Services (Centers for Disease Control and the National Institutes of Health), Food and Drug Administration, Department of Defense and the Department of Energy's National Laboratories (see appendix A for participants).

The specific goals of this Technology Assessment and Roadmap were to:

- Describe the general context for deployment of emergency radiation dose assessment tools following terrorist use of a radiological or nuclear device
- Assess current and emerging dose assessment technologies
- Put forward a consensus high-level technology roadmap for interagency research and development in this area.

Below we provide a summary of the consensus of needs, gaps and recommendations for a research program in the area of radiation dosimetry for early response, followed by a summary of the technologies available and on the near-term horizon. We then present a roadmap for a research program to bring present and emerging near-term technologies to bear on the gaps in radiation dose assessment and triage. Finally we present detailed supporting discussion on the nature of the threats we considered, the status of technology today, promising emerging technologies and references for further reading.

Needs Evaluation

In the event of a terrorist-driven radiological event, emergency radiation dose assessment by first responders will be necessary to identify and focus the use of precious medical resources. Terrorist-driven exposure to radiation can result from several forms of radiological or nuclear devices (R/N), ranging from non-explosive, and clandestine exposure to a radiation source, to explosively-driven radiological dispersion devices (RDD), and even improvised or stolen nuclear weapons (IND). Incidents may result in external exposure (radiation dose, without the presence of radioisotope(s) in or on the body) and/or the uptake of radioactive materials by inhalation, ingestion, skin absorption, wound contamination or injection of radioisotope(s) as embedded

material. In many instances, emergency response personnel are the first medical responders to contact victims. In other cases, the medical treatment facility itself serves as the “first response” center. In both cases rapid evaluation of patients is key to early initiation of medical intervention and ultimately to saving lives.

Tools to rapidly triage individuals needing medical attention and to intelligently direct medical treatment to those needing immediate care will optimize the use of scarce resources, improve survival, and enhance public confidence in government. It is imperative that victims who have been exposed to significant levels of radiation following a terrorist event, especially one involving an IND or stolen nuclear weapon, be identified and sorted from those that are concerned that they have been exposed, but who have received no or a non-health threatening radiological dose as rapidly as possible so that treatment can be administered to those in need. This is no small task as it is expected that for every person requiring medical attention, 100 – 500 persons concerned about their possible exposure will request medical evaluation, thus taking up precious time and resources. The more rapidly this can be carried out the faster precious medical resources can be focused on those in need of medical intervention.

Radiation dose assessment is critically important because medical treatment depends on understanding the dose an individual receives. Treatment guidance will depend on the therapy type employed. Currently, medical intervention depends on the patient's medical signs and symptoms resulting from the radiation dose received which, in turn, depend on distance from the initial event and exposure to fallout. Immediate treatment is needed for otherwise healthy persons who have had whole or near-total body radiation exposure exceeding 2 Gy. 3.5-4.5 Gy exposure, without treatment, would result in at least 50% mortality within 3 to 6 weeks. Combined injury (radiation and burn/blast trauma) lowers the threshold for treatment to 2 Gy. In addition to the clinically significant doses that could be received, with some radiological scenarios such as an RDD or “dirty bomb,” many victims may have severe levels of internal contamination from inhalation of the radionuclide(s) dispersed by the bomb. Current medical guidance recommends that treatments for internal contamination should begin within hours of exposure (Ceverny, 1989).

Patients with very high radiation doses or significant internal contamination will likely present with no clinical symptoms other than possible conventional trauma. In most cases radiation sickness takes days to weeks to present clinical manifestation. The severity of the resulting lesions and time of onset depends, in part, on the delivered dose and how soon interventions are begun. Medical management and decisions regarding initiation of simple interventions such as removal of contaminated

clothing and washing of the body; early initiation of more aggressive therapies such as chelators for reducing internalized radionuclide dose, cytokines for reducing the effects of bone marrow suppression and others depend on knowledge of expected clinical responses. Clinical response is correlated with acute radiological dose. Current state-of-the-art practice for determining acute radiation doses relies on three methods:

1. Time-to-onset and severity of nausea and vomiting
2. Lymphocyte depletion kinetics
3. Chromosome aberration cytogenetics.

Presently available methods are not satisfactory for managing the medical casualties from an R/N event and there is urgent need to develop new capabilities to assess radiation dose quickly with at least moderate precision. Assessment of emesis is only a rough indicator of acute exposure and can never be relied upon alone, especially for quantitative information. Lymphocyte depletion provides direct quantitative information but requires analyzing peripheral blood samples from the patient over a period of 12 hours to 7 days, while chromosome aberration analysis requires a qualified cytogenetic laboratory and 48 to 72 hours to analyze after sample receipt. Because none of these methodologies alone are reasonably satisfactory for managing mass casualties from a large RDD or an IND event in the first few hours, there is an urgent need to develop novel emerging technologies to supplement the current capabilities for assessing emergency radiation doses.

Technology Gap

Within the first 72 hours tools are needed that can detect whole body doses of between 1-8 Gy and can run at a rate of 1 assay every 5 minutes. These tools presently do not exist.

Based on radiological and nuclear weapons scenarios that range from clandestine sources to full-scale nuclear weapons, combined with decision-point dose levels recommended by current medical consensus on triage and treatment, the following throughput, turnaround time, sensitivity, and range are used as generally ideal reference points for emergency-response dose assessment tools:

- Hand-held diagnostic device with throughput of 1 assay per 5 minutes or less
- Field-laboratory turnaround time of 24 hours or less
- Hand held field laboratory and reference laboratory radiation dose assessment systems need a detection range 1-8 Gy, with thresholds at 1.5 Gy and 4.5 Gy for triage and 2-3 Gy and 6-7 Gy for treatment decisions for hand-held, field laboratory, and reference laboratory diagnostic dose assessment system.

- Critical need to identify those who do not need immediate medical attention

Recommendations and Priorities

A research and development program focused on providing simple tools that can provide an estimate of whole or near whole body radiation dose is needed which can discriminate approximately 2 Gy and 4 Gy exposures from background and can provide throughput of 1 assay per 5 minutes or less. A process leading to fielding such devices is possible within the next 5 years. The goals of this program should be to:

Clarify device needs and requirements

- Combine user input, technology assessment and operations/systems studies to guide development of realistic requirements and appropriate system architectures for radiation dose assessment tools.
- Focus initial studies on defining the role of pre-positioned dosimeters, optimizing the size and organization of a national cytogenetics network, and estimating the added value of dosimetry technologies still on the horizon, such as luminescence, ultrasound, and molecular markers of radiation dose and injury. Prioritize investment based on user input, available technology capabilities and operational needs developed under the first bullet.
- Develop a clear set of decision points to determine whether individual technologies are on track to be deployed, and define a path/mechanism for deployment.

Maximize use of existing technologies

- Concentrate near-term technology investments in developing pre-positioned dosimeter concepts and establishing a stable U.S. cytogenetics capability for use in the event of an R/N incident, in line with the results of systems studies to assess their relative value in saving lives for realistic radiological or nuclear events.

Pursue longer-range research and development to fill gaps with existing technologies

- Answer key questions about the throughput, specificity, prognostic value, sensitivity, range, accuracy and reliability (including person-to-person variability and impact of confounding factors) for new radiation dose and injury assessment technologies.

Conduct a demonstration program to assess the value of existing and proposed technologies

- Conduct field tests and leverage already-scheduled events to assess systems-study assumptions, new-device performance, and concepts of operation in an operational environment.



Technology Summary

Technology Assessment

Table 1 summarizes what we know and don't know about current and emerging technology for emergency dose assessment and triage. Overall, the prospects of current technologies meeting emergency-tool assessment criteria are limited:

- Direct measurement of external radioactive emissions on body surfaces and clothing is a standard tool for first responders. High throughput screening for qualitatively detecting overt contamination is possible with portable probes for many isotopes. This technology is viewed as an important tool by first responders for triage decision making in the first hours following a detonation, primarily for use in decontamination decisions. Early external decontamination removal is important to reducing whole body radiation dose. However, it only provides an estimate of the dose received from external contamination on the clothing and body at the time of measurement and this dose may be a small component of the total dose received by the victim, depending on the type of terrorist device used.
- Direct external measurement of radioactive emissions *in vivo* originating in the body is a practical solution for measurement of internal radioactive contamination; however high-throughput sample-processing systems and quick-reference guidance for converting contamination measurements do not exist. These technologies are important to long-term case management and could be useful for early initiation of relevant therapies.
- Pre-positioned dosimeters generally perform well for dose assessment criteria; the most cost-effective and easy-to-read candidate, the SIRAD card, currently has limited distribution with a shelf-life reported to be one-year when stored properly.
- Conventional cytogenetic assays are presently considered the standard for estimating whole body biological dose. Such assays have demonstrated capability to estimate doses below 1 Gy in a controlled laboratory setting. However, use of cytogenetics in a triage situation is difficult below 1 Gy, and standard assays take 48-72 hours to complete. Shorter-turn around (24 hours) assays are not yet well benchmarked or available.
- Lymphocyte depletion is not detectable following radiation doses of less than 5 Gy within the first 24 hours, and lymphocyte kinetics which require serial measurements of 3 or more counts, exhibits a dose threshold near 1 Gy but likely will be logistically difficult to obtain within this time period after a mass casualty incident without development of a hand-held blood counter device.

- Dose assessment based on time-to-vomiting, has variable sensitivity with only 35% of victims vomiting after a 2 Gy exposure and >90% incidence following 6 Gy exposure; dose assessment based solely on use of prodromal symptoms including time-to-vomiting will likely exhibit significant false positives.

Emerging technologies offer potentially significant advantages, but present substantial uncertainties that must be resolved:


- Molecular biomarkers, including mRNA and proteins, offer a new set of tools for hospital-based, fieldable, or even self-administered radiation dose assessment. However, research is necessary to assess person-to-person variability and impact of confounding factors such as stress, gender, and age among others. Prototype devices must demonstrate sensitivity (as well as cost, size/weight, and ruggedness) in realistic test scenarios.
- Luminescence, particularly Optically Stimulated Luminescence (OSL) and Electron Paramagnetic Resonance (EPR-ESR) are technologies that have the potential for measurement of radiation doses *in vivo* at or below the 1.5 Gy thresholds in human tissues. Sensitivity and inter-individual variations must be demonstrated experimentally. Prototype devices must be built and tested for cost, size/weight, performance, and ruggedness.
- Ultrasound is a particularly exciting opportunity for assessing tissue damage from radiation and may have much broader applications. Sensitivity, as well as person-to-person variation is not known. Operability in the field has not been demonstrated and fieldable hospital-based prototypes require development and evaluation.
- Fortuitous dosimeters promise simple, accurate dose estimates from common objects that may be at or near the victim(s), using luminescence as the primary approach for readout. However the value of relying on fortuitous objects which may or may not be available, in an emergency setting needs to be demonstrated. Accuracy and sensitivity, cost, size/weight, performance, and ruggedness are presently unknown. Concepts of operation are not developed.
- Hand-held devices for blood cell counting, breath-gas analysis, and medical recording, tagging of casualties, and triage tools should be explored and could be an essential part of the response system. The utility of these tools and how best to use them are somewhat undefined. Current recording criteria identified for emergency tools should be expanded to include plume/position-based dose estimates as well as newer dosimetry tools as they become available.

Even if technologies do not meet operational requirements, they may still have useful applications in response to a radiological or nuclear event. An example of this is cytogenetics, the gold standard for biodosimetry: even though likely

throughputs and turnaround times do not match the needs described above, cytogenetics will no doubt prove invaluable in directing treatment for those already identified for as in need.

Table 1. Summary of what we know and don't know about current and emerging dosimetry technologies.

	What we know	What we don't know
Current Methods and Tools		
Measurement of radioisotope contamination	Many available handheld detectors for external assessment. Internationally accepted guidelines for radiation dose estimation. Available instrumentation for body fluid analysis, limited high-throughput capability.	Radiation dose estimation models need more attention, and may have significant inaccuracies, especially for sub-populations.
Biological and clinical signatures of radiation dose	Lymphocyte depletion is not detectable in the first 24 hours for less than 5 Gy. Lymphocyte kinetics will be logistically difficult to obtain within this time period and vary significantly from individual to individual. Time-to-vomiting is limited in sensitivity (only 35% of victims vomit with a 2 Gy exposure) and is widely variable from individual to individual. Conventional/cytogenetic chromosome aberration assessment (scoring 1000 metaphase spreads) takes 48-72 hours and has demonstrated capability to estimate doses from 0.20 to 6.0 Gy (acute photon equivalent dose), while cytogenetic triage (scoring 40-50 metaphase spreads) becomes difficult below 1 Gy. The current U.S. cytogenetics capability is limited to less than 500 standard assessments over a 2-week period. These methods may not accurately predict partial-body or organ-specific exposure.	Effect of dose rate on lymphocyte counts or depletion rate is not known. Psychosomatic impact on time-to-vomiting is not established for a mass casualty situation. Shorter-turnaround (24 hour) cytogenetic chromosome aberrations are not yet well benchmarked.
Pre-positioned physical dosimeters	Current technology meets dose threshold and dynamic range requirements. May not accurately predict partial-body or organ-specific exposure.	Shelf-life, longevity not well established for SIRAD cards. Social and medical questions about how to interpret "significant radiation exposure" readings and false positives.
Emerging Technologies		
Physical changes in human tissues	OSL and EPR could enable accurate and safe estimation of dose from non-invasive <i>in vivo</i> measurements in teeth, with a threshold at or below 1.5 Gy. Ultrasound may provide evidence of local radiation injury around wounds. Potential for turnaround and throughput in 1 min / assay timeframe.	OSL sensitivity significantly below 15 Gy is anticipated from theoretical arguments, but has not yet been established experimentally. <i>In vivo</i> EPR dosimetry sensitivity and potential inter-individual variation effects are unknown. OSL and EPR field equipment (portable, etc.) has not been demonstrated. Dose sensitivity of ultrasound is not established.
Personal items and other fortuitous dosimeters	Several materials have been demonstrated to provide very accurate dosimetry, with a detection threshold well below 1.5 Gy. Potential for turnaround and throughput in 5 min / assay timeframe. Hard to depend on this approach for all victims, since dosimetry materials are fortuitous. May not accurately predict partial-body or organ-specific exposure.	Con-ops and instrumentation for widespread use have not been established.
Biological markers	Several mRNA and protein candidates demonstrated to be dose dependent, with sensitivity well below the 1.5 Gy action threshold. Hand-held devices for blood cell counting, breath gases analysis, and triage medical recording involving the tagging of casualties will assist with triage. Instrumentation concepts (protein and PCR assays) have been demonstrated for other applications, and could provide 5 min turnaround and throughput and / or be run in a highly multiplexed format. Potential for a self-administered disposable format for proteins. May not accurately predict partial-body or organ-specific exposure – this could be addressed with significant further research.	Time dependence and variation with confounding factors such as age, stress, and health status have not been well established. Instrumentation throughput, ruggedness, accuracy and sensitivity have not been established for this application. Organ-specific markers have not been established. Utility of other biological markers such as metabolites need investigation. Ability of markers to detect/differentiate whole or partial body exposures are unknown.



What Should be Done

Roadmap for a National Program in Emergency Radiation Dose Assessment

Table 2 lays out a roadmap, a set of deliverables, and a rough timetable for a National Program in Emergency Radiation Dose Assessment. We advocate the development of a cooperative, interagency program to efficiently develop capabilities, both near and far-term, that could have a major impact on the management of victims and the potentially exposed individuals in the aftermath of the detonation of an RDD or IND. We focus on what will be needed within the first 72 hours following an event to determine who will be in need of follow-up care or medical surveillance. This proposed program has four major goals:

1. Clarify device needs and requirements
2. Maximize use of existing technologies
3. Pursue longer-range research and development to fill gaps with existing technologies
4. Conduct a demonstration program to assess the value of existing and proposed technologies and optimize their development for fielding and commercialization.

Below is a brief discussion of priority investments for each of these goals.

Clarify device needs and requirements

The expected user community should be polled to determine the needs and requirements for the technology to be used in deployments. The requirements developed should be device and application specific. Many factors must be considered in the choice and design of this technology including:

- Desired throughput
- Specificity
- Ease of use (level of training required to operate the equipment)
- Sensitivity
- Time to complete the assays
- Result integration for end-user application
- Allowable false positive/negative rates
- Sample matrices/ease of sample collection and processing
- Shelf life
- Costs (manufacturing/use)

The requirements may differ depending on the intended use of the devices. For example field triage devices may have a different set of requirements for cost and ease-of-use than devices used in clinical settings. The exact scenarios of use and expectations must be determined.

User input and technology assessment should be used to inform quantitative operations/systems studies to guide con-ops and medical response architecture development and help prioritize science and technology investments. The initial focus should be on:

- Developing a national cytogenetics network with each reference laboratory supplemented by satellite scoring laboratories capable of each analyzing 500 samples per week.
- Defining the role of pre-positioned dosimeters.
- Estimating the added value of radiation injury and dose assessment technologies still on the horizon, such as luminescence, electron paramagnetic resonance, ultrasound, molecular markers of radiation dose, and hand-held devices for bioassay (blood cell counting, breath gases, etc.) measurements and recording/tagging of individuals.
- Developing a clear set of decision points and critical development paths to determine whether individual technologies are on track to be deployed, and define a path/mechanism for deployment.

Maximize use of existing technologies

Near-term technology investments should be concentrated on building a U.S. cytogenetics capability and developing pre-positioned dosimeter concepts, in line with the results of systems studies to assess their relative value in saving lives for realistic radiological or nuclear events. A deployable hematology capability should be investigated as an available resource, following the IAEA ERNET model, to provide the ability to supplement local capabilities for serial blood cell counts on suspected radiation casualties. Radioisotope contamination assessment laboratories should be equipped with high-throughput sample-assessment systems based on existing commercial-off-the shelf (COS) technologies.

Pursue longer-range research and development to fill gaps with existing technologies

Longer-range research and development should be conducted on emerging dosimetry technologies to answer key questions about the specificity, prognostic value, throughput, sensitivity, range, accuracy and reliability (including person-to-person variability and impact of confounding factors). A variety of technologies are presently in the marketplace for diagnosis of a number of diseases. Some of these technologies may be useful for radiation dose assessment with minimal development. Evaluation of potentially useful technologies should be carried out and emphasis placed on their conversion for use in radiation dose assessment.

Conduct a demonstration program to assess the value of existing and proposed technologies

Finally, field tests, conducted as stand-alone studies as well as piggy-back exercises attached to already-scheduled events, should be done to assess operational assumptions, new-device performance, and con-ops in an operational environment.

Table 2 summarizes a strategic 5-year roadmap to accomplish these goals.

Table 2. Suggested Goals for National Program in Radiation Assessment.

	1 year	1 to 3 years	3 to 5 years
Systems analysis to clarify device needs and requirements	Analyze scenario for one radiological and one nuclear incident type. Define relative roles of physical and bio-dosimetry, perform cost-benefit analyses for dosimetric systems.	Provide initial estimate of operational device requirements for R/N scenario's for physical and bio-dosimetry tools. Evaluate hospital instruments and technicians to determine capability to perform required measurements.	Refine estimates based on progress in laboratory experiments and initial field demonstrations. Work with instrument manufacturers to modify hospital-based instruments to be capable of measuring threat isotopes, and provide training to technicians.
	Determine optimum size and organization of a national cytogenetics network. Evaluate competing technologies and define the most effective role of pre-positioned dosimeters. Develop criteria to distinguish the added value of emerging dosimetry technologies. Evaluate and compare competing technologies to select the best available.		
Short-range efforts to maximize use of existing technologies	Define a blueprint to stabilize a U.S. cytogenetics capability and developing pre-positioned dosimeter concepts. Establish deployable hematology capability - radiation response team resource.	Establish a national cytogenetics laboratory network composed of reference laboratories supplemented with satellite scoring laboratories. Develop high-throughput sample-assessment system for radioisotope contamination. Pilot pre-positioned dosimeters.	Test system in well-controlled round robins and practice exercises. Establish standardized cytogenetics protocols and develop standard calibration curves.
Longer-range research on emerging dosimetry technologies	Initiate parallel efforts in emerging physical and biological dosimetry, define decision tree for technology assessment.	OSL, EPR and ultrasound: assess sensitivity, person-to-person variability, and safety of prototype systems. Hand-held breath gas analysis, blood cell counters, and triage medical recording/ tagging systems.	Develop working prototypes for con-ops and performance-based down select after ~year 5.
		Fortuitous dosimeters: develop con-ops, develop and assess field prototype detectors. Molecular markers: demonstrate sensitivity, person-to-person variability / sensitivity to confounding factors; demonstrate field prototypes that meet sensitivity and other operational requirements.	
Demonstration programs	Define a field demonstration plan that leverages state and national exercises.	Conduct field demonstrations that verify performance of existing technologies.	Conduct field demonstrations of emerging dosimetry prototypes.



Supporting Information

A. Context for the Use of Emergency radiation Dose Assessment Tools

1. Event Characteristics and Diagnostic Requirements

Terrorist-driven exposure to radiation can result from several forms of R/N devices, ranging from non-explosive, clandestine exposure to a radiation source, to RDD, and even IND. Incidents may result in external exposure (radiation dose, without the presence of radioisotope(s) in or on the body) and/or the uptake of radioactive materials by inhalation, ingestion, skin absorption, wound contamination or injection of radioisotope(s) as embedded material. In many instances, emergency response personnel are the first medical responders to contact victims. In other cases, the medical treatment facility itself serves as the “first response” center. We did not consider attack on a nuclear facility, as this scenario has already been well-studied and planned by the Nuclear Regulatory Commission.

A nuclear weapon detonation may result in exposure to α -particles, β -particles, γ -rays, X-rays, and neutrons, with over 400 radionuclides possibly being released. However, only about forty of the released radioisotopes are likely to be hazardous to humans. (NCRP 65 1980; Durakovic, 1987; Cervený, 1986). The most significant radioisotopes from unspent nuclear fuel are tritium, plutonium, and uranium. Radioisotopes of immediate radiological significance include isotopes of americium, californium, cerium, cesium, curium, iodine, plutonium, polonium, strontium, and uranium, as well as tritium. (Cervený, 1986)

For radioactive contamination, early information on the history of the exposure incident may identify the major isotopes involved and provide some dosimetry information. Causalities will likely present with no clinical symptoms other than possible conventional trauma (Cervený, 1989).

In most scenarios, the number and type of individuals that require evaluation changes, often significantly, over time following the event. In the first hour following detonation, it is expected that there will be potentially 100's of treatable radiological victims with external and internal radioisotope contamination and explosive trauma injury. At slightly later times (24 hours), victim makeup will likely shift to those with radiological contamination, minor trauma and many self-identified individuals who have some or no contamination but who still need evaluation. Beyond the first day, victims will likely consist of those who have some radiological contamination from plume exposure and many, potentially in the hundreds-of-thousands, who self identify with concerns about being exposed. In the case of the detonation of a nuclear weapon, many of those individuals are likely to be seriously exposed.

In response to the changing number and nature of the causalities, the types and needs of first responders and receivers also change. Initially, fire fighters, paramedics, law enforcement and good Samaritans will need tools for assessing radioisotope contamination and rapid dose assessment for triage in the field so that decontamination and life-saving activities can be managed. Later, high-throughput radioisotope contamination detectors and rapid dose assessment tools will be needed to assist with finding those in need of chelation, cytokine or other therapy and sending concerned citizens, with little or no exposure, home. A means to later identify victims in the early response phase following detonation will be crucial for longer term follow-up. Overall, there are four classes of device needs (here we focused on categories 1-3):

1. Radioisotope contamination detectors and radionuclide dose assessment:

These detectors range from simple Geiger-Muller-type detectors to instruments for assessing body fluids and other products, and computational tools for converting measured counts or activity to an estimate of and/or committed dose. Of equal importance is a simple, robust way to rapidly predict committed dose from detected counts. First responder concepts of operations will likely rely on such tools for early decision making concerning the need for decontamination and whether it's necessary to initiate more aggressive therapies to limit possible organ system failure. These concerns along with the first priority, first aid, will be important issues in the early stages of an event.

2. Dose assessment tools that do not rely directly on counting radioactive emissions:

In many cases, particularly when significant dose is delivered from distant external radiation sources such as from delayed γ -radiation including ground shine, the level of radioactive contamination may not accurately provide an estimate dose. The accuracy and threshold(s) required of dose assessment tools will depend on the type of triage / assessment capabilities available, particularly on whether other injuries are present.

3. “You’re ok” markers to avoid multiple evaluations of the same individual:

In all scenarios, the concerned citizens with no real exposure pose a significant and important component of those being assessed for potential radiation dose.

Importantly, the number of these individuals is likely to measure in the thousands for all scenarios proposed and will drain resources, potentially reducing the capability to treat highly exposed persons. Reliable tools to discriminate those who do not need further immediate care avoids the wasting of critical dose-assessment and response recovery resources.

4. Tags for future tracking:

Many individuals, often numbering in the thousands, both those who may need active care and those who do not, will be monitored for decades for long-term radiation effects. An efficient system for tagging these individuals and recording their initial location at the time of exposure will provide invaluable information for this long-term follow-up.

For each device, throughput and complexity are key considerations. The throughput requirements for each of the dosimetry devices depend on the type of scenario and time after the event when the device will be used. These factors affect the expected ratio of individuals to be assessed to number of responders and devices placed in use. Tolerance for device complexity depends on whether it is used by hospital personnel, firefighters, or even individual victims as a self-administered test and the environment in which the device is to be operated (i.e., in the field at the site of an event vs. in a hospital). However, in all cases, devices must feature simple sample collection, preparation, and results output, because of the likely confusion surrounding a radiological or nuclear event, compounded by their extreme rarity.

2. Triage and Initiation of Treatment

The International Atomic Energy Agency (IAEA) has provided consensus guidelines for a comprehensive description of procedures for medical response during a nuclear or radiological emergency (IAEA, 2005). Requirements for sensitivity and dynamic range for emergency dosimetry strategies and technologies are related to current (and future) medical guidance for triage and initiation of treatment. Ideal medical management recommends early administration of treatment.

Lives may be saved if we can develop rapid dose assessment and can implement earlier treatment. Specifically, ideal medical management recommends early administration of treatment because much large animal data (McVitte, 1996) and some human accident data (Gusev, Guskova, and Mettler, 2001) strongly suggests that early treatment with cytokines can significantly increase survival following external radiation exposure to the hematopoietic system of more than 2 Gy. This is

because early cytokine therapy can mitigate significant white blood cell depletion and the subsequent mortality from infections. There is a clearly identified gap in technology for identifying individuals with a clinically significant dose within the first 36 hours after exposure.

Radiation Injury Assessment and Triage Treatment.

Current civilian medical guidance (Waselenko, 2004) advocates two possible triage systems, one based on a modification of the military triage system (Walker and Cervený, 1989) used in mass-casualty scenarios and another based on grading of clinical signs and symptoms (Dainiak, 2002; Fliedner, 2001). In the pre-dosimetry clinical signs and symptoms scheme, an initial response category is assigned by determining the degree of damage to the cutaneous, gastrointestinal, and neurovascular systems. Further categorization of patients based on degree of hematologic damage permits triage to an ambulatory setting, admission to a routine-care hospital floor, or admission to a critical care unit. This system is very useful to the clinician in management of a small-volume radiologic event. However, it is time-consuming and may be impractical in a large-volume scenario.

In the military-based triage system, priorities for treatment change, depending on how the patient is evaluated in terms of radiation dose and the presence or absence of significant mechanical trauma or burns. (Waselenko, 2004)

“Individuals requiring surgical intervention should undergo surgery within 36 hours (no later than 48 hours) after exposure (Walker and Cervený, 1989). Additional surgery should not be performed until 6 weeks later.”

Recommended triage priorities are summarized in Table 3, according to the Strategic National Stockpile – Radiation Working Group (Waselenko, 2004):

“At a whole body dose <1.5 Gy, triage categories remain the same: delayed treatment for those who are medically stable with significant injury but who may survive until definitive treatment is available; 2) immediate therapy for those with high survivability and significant injury, provided that immediate therapy is available; 3) minimal therapy for medically stable patients with minor injury; and 4) expectant therapy for patients who are seriously injured and in whom survivability is poor. All patients with the combined injury syndrome and exposure dose >4.5 Gy should be treated expectantly, except for those with minimal or no injury. Patients with radiation injury alone (i.e., without combined injury) should be triaged to the ambulatory setting if dose

<1.5 Gy. For those with a higher exposure dose, routine care should include therapy with cytokines, antimicrobial agents, blood transfusion and frequent outpatient follow-up with laboratory monitoring.”

Consensus guidelines for treatment of radiologic victims (Waselenko, 2003) are summarized in Table 4. Radiation dose is described as photon dose equivalent, and values are provided for adults (consider initiating therapy at lower radiation dose for non-adolescent children and elderly persons). Cytokines would be among the first agents administered to the group of significantly irradiated individuals who have the treated survival potential. A significant survival advantage has been demonstrated in irradiated animals treated with colony-stimulating factors (cytokines) in the first 24 hours. (Waselenko, 2004). Prophylactic antibiotics are also a treatment component to be considered but should be addressed on a case-by-case basis.

Radioisotope Contamination

Thorough evaluation and estimation of internal contamination may take days or weeks, so initial decisions may have to be based only on local information and superficial measurements. Because rapid initiation of decontamination therapy both increases the effectiveness of the therapy and reduces the absorbed dose in the body, medical personnel must proceed quickly to obtain information and make treatment decisions based on available early estimates of possible exposure. Initial response will be to remove contaminated clothing and wash

radioactive victims to remove contamination from the body surface. Therapy for internal contamination will likely begin somewhat later. Treatment risks must be weighed against the presumed risks of untreated exposure, and treatments for internal contamination should begin within hours of exposure. (NCRP Report 65, 1980; Durakovic, 1987; Cervený, 1986; ICRP, 1955; Conklin, 1983; Moskalev, 1974; Cosgriff, 1987). More detailed radioisotope monitoring and radiation absorbed dose estimation may continue for days to weeks after treatment has been initiated. Although decontamination should be done as quickly as possible, the stability of an injured patient is vital, and first aid must be the primary concern (Cervený, 1989) followed by removal of external sources of contamination.

3. Diagnostic Requirements for Sensitivity, Accuracy, Throughput and Turnaround Time

The military-based triage system, as well as the proposed consensus guidelines for treatment, assume a method for establishing radiation absorbed dose. Key decision points revolve around 1.5 and 4.5 Gy for triage, and 2-3 and 6-7 Gy for direct treatment of radiation injury. These action dose levels set a lower sensitivity limit of no greater than 1 Gy, and dosimetric uncertainties of less than about 20-30%. Because available data on exposure estimates have significant inherent uncertainties themselves, it is difficult to estimate the ideal dosimetric accuracy for emergency response and triage. Thus the above decision levels are based on the best available information and provide consensus starting points. Further research may be needed on this point.

Table 3. Priorities in triage of patients with and without combined injury, based on dose of radiation (military-based triage scheme) (Waselenko, 2004).

Conventional Triage Categories for Injuries without Exposure to Radiation*	Changes in Expected Triage Categories after Whole-Body Radiation		
	<1.5 Gy	1.5 – 4.5 Gy	>4.5 Gy, 10 Gy
Delayed	Delayed	Variable	Expectant
Immediate	Immediate	Immediate	Expectant
Minimal	Minimal	Minimal	Minimal
Expectant	Expectant	Expectant*	Expectant*
Absent	Ambulatory Monitoring	Ambulatory monitoring with routine care and hospitalization as needed	

*Although other injuries may be minimal, treatment guidelines should be followed for patients receiving a whole-body radiation dose greater than 3 Gy.

Table 4. Guidelines for treatment* of radiologic victims (Waselenko, 2004).

Variable	Proposed radiation dose range for treatment with cytokines	Proposed radiation dose range for treatment with antibiotics	Proposed radiation dose range for referral for stem-cell transplant consideration (SCT)
Small-volume scenario (≤100 casualties)			
Healthy person, no other injuries	3-10 Gy	2-10 Gy	7-10 for allogeneic SCT; 4-10 if previous autograft stored or syngeneic donor available
Multiple injuries or burns	2-6 Gy	2-6 Gy	
Mass casualty scenario (>100 casualties)			
Healthy person, no other injuries	3-7 Gy	2-7 Gy	7-10 for allogeneic SCT; 4-10 if previous autograft stored or syngeneic donor available
Multiple injuries or burns	2-6 Gy*	2-6 Gy*	NA

* If resources are available, see reference (Waselenko, 2004) for additional details.

Ideal timescales for obtaining dosimetry information can be estimated from what are presently considered as optimal therapy initiation times. Radionuclide decontamination treatment should be initiated within hours of exposure. For direct treatment of radiation injury, cytokine therapy should be initiated within 24 hours after exposure, leading to a goal of completing initial triage / screening for radiation injury victims within this 24 hour time frame. Upper limits for processing time may be related to onset of radiation sickness syndromes, which would presumably make radiation exposure self-evident. However, in the case of a nuclear weapon detonation, presence of high radiation levels may prevent access to the scene for 24 hours or more. Thus turn around time of less than 24 hours is needed for maximal benefit from such therapy. The gastrointestinal syndrome follows a latent period of 5-7 days. Cytopenia associated with the hematopoietic syndrome becomes evident within 24-48 hour for lymphocytes, 5-30 days for neutrophils, and ~15 – 30 (nadir) days after exposure. If identifying patients substantially before gastrointestinal syndrome onset is used as an upper limit for processing times,

3 days seems to be a reasonable upper limit for processing patients who have been potentially lethally exposed to radiation. Beyond 5-10 days, the gastrointestinal syndrome is self-evident and blood counts may serve as a reasonable indicator of exposure for predicting hematopoietic syndrome.

These timescales suggest an ideal assay processing turnaround time of 24 hours. For throughput estimate purposes, assume a processing goal of initial assessment completed within 24-72 hours, and an estimated 100,000 individuals to be evaluated (this could be a representative figure for expected radiation injuries for fallout following a nuclear weapon explosion, and would include mostly concerned individuals for most radiological dispersal scenarios). Also assume 100 individuals to be assessed in parallel. To achieve the evaluation within these parameters, the initial triage bioassay for each individual radiation-injury assay must be completed in 1-4 min. Clearly, this is difficult to envision without additional investment in technology enhancements.

B. Current Methods and Tools for Triage and Emergency Dose Assessment

The consensus generic approach for medical management of radiation casualties involves use of multiple parameter biological symptoms and bioassays, physical dosimetry, and radioactivity contamination assessment for radiation injury and dose estimation. Individual dose assessment is essential for predicting the clinical severity, treatment, and survivability of exposed individuals and identifying those with minimal or no exposure.

In the case of a radiological mass casualty incident the initial triage response should focus on screening these large populations for clinically significant doses with 1-Gy threshold sensitivity. The individual technology components, including physical dosimeters, of the multiple parameter dose assessment approach, need Food and Drug Administration regulatory review and approvals if applied for medical treatment decisions.

This section describes current methods and instrumentation that could be used for triage and emergency dose assessment.

1. Biological and Clinical Signatures of Radiation Dose Assessment

Currently, the three most useful biological / clinical signatures determining radiation injury and accumulated dose are time to onset of vomiting, lymphocyte depletion kinetics, and the presence of chromosome aberrations (Waselenko, 2004). A radiation casualty management software program, the Biological

Assessment Tool, is available at the Armed Forces Radiobiology Research Institute's Web site (www.afri.usuhs.mil). This tool was developed in collaboration with the Radiation Emergency Assistance Center/Training Site (REAC/TS) and others to facilitate medical recording and estimation of individual dose (Sine, 2001). The IAEA has developed generic guidelines for recording clinical signs and symptoms of radiation injury (see www.iaea.org). Using a grading system for the severity of clinical symptoms, the Medical Treatment Protocols team has developed a quantitative system to assess individual biological response to radiation exposure when results of chromosomal analysis are not yet available (Fliedner, 2001).

The time-to-onset and percentage of victims with vomiting is related to radiation dose received. Greater than 90% of those receiving 6 Gy or more will present with an average time-to-onset of vomiting within an hour. In the 1-3 Gy range, between 20-50% of victims show signs of vomiting, with an average time-to-onset of greater than 2 hours. However, this assay relies on victim recall and results are variable among individuals.

Absolute lymphocyte counts decrease with increasing dose and increasing time from exposure. In the first 12 hours, only doses of 9 Gy and higher are expected to result in absolute lymphocyte counts that exceed the lower normal bound. This lower bound will be exceeded for approximately 5 Gy and 3 Gy exposures, after 24

and 48 hours, respectively. The rate constant for lymphocyte depletion increases with dose. Figure 1 shows the variation in lymphocyte kinetics and time-to-vomiting, based on accident victim data. (Goans and Waselenko, 2004).

Dose assessment based on cytogenetic chromosome aberration biodosimetry represents a well established and proven bioassay for radiation dose assessment (10 cGy threshold in a good laboratory). Radiation exposure induces many types of chromosomal aberrations in the exposed individual's peripheral blood lymphocytes. The presence of dicentrics, a chromosomal aberration, in an individual's peripheral blood lymphocytes indicates radiation exposure (Bender and Gooch, 1966). Dicentrics are considered relatively specific, to ionizing radiation; only a few chemicals are known to interfere with the assay. Low background levels (about 1 dicentric in 2000 cells),

high sensitivity (a threshold dose of 0.05 Gy), and known dose dependency of up to 5 Gy (for acute photon exposures) make this assay robust and a "gold standard" biodosimetry method.

The IAEA published a technical manual containing a harmonized methodology for various cytogenetic assays (IAEA, 2001). An International Organization for Standardization (ISO) working group was established to standardize biological dosimetry by cytogenetics. Under the auspices of the ISO, regulatory compliance and validation standards have already been developed (Voisin 2002). This ISO working group is now focusing on developing the standard titled "Radiation Protection — Performance Criteria for Service Laboratories Performing Cytogenetic Triage for Assessment of Mass Casualties in Radiological and Nuclear Emergencies." This standard will define the process and identify quality control standards for the use of cytogenetic methods to rapidly assess radiation dose, information that will supplement the early clinical categorization of casualties.

The use of cytogenetic assays to guide treatment decisions was demonstrated in radiation mass casualties for example, Chernobyl, Goiania, and Tokaimura. Dose estimates from cytogenetic methods correlate well with the severity of acute radiation syndrome (Sevan'kaev 2000). In the Chernobyl accident an approximate dose estimate was achieved by rapid preliminary examination of metaphase spreads (Pyatkin 1989). From the Goiania (Brazil) accident cohort, 129 exposed or potentially exposed individuals were investigated by cytogenetics (Ramalho and Nascimento 1991). More recently, in the Tokaimura, Japan, criticality accident, the dicentric and premature chromosome condensation (PCC) assays were used to assess the dose for three severely exposed workers (Hayata 2001; Kanda 2002) and 43 resident workers (Sasaki 2001).

Rapid response is required from specialized cytogenetic biodosimetry laboratories in the case of a mass-casualty scenario for potentially thousands of individuals (Voisin, 2001; Prasanna, 2003). Due to requirements inherent in the standard assay, results are not available for 48 to 72 hours after the sample has been submitted for analysis. These time gaps limit standard cytogenetic bioassay to be an important tool for dose




Figure 1. Dose response calibration curves for lymphocyte depletion kinetics and time-to-vomiting. These data illustrate the radioresponse for two major indicators used to provide a triage dose assessment based on radiation doses of record derived from γ -ray accidents, criticality accidents, and Chernobyl (Goans and Waselenko, 2004: presented at the 2004 NCRP annual scientific meeting).

assessment, but not for direct use at the emergency scene. A requirement for the emergency scene, however, is obtaining blood samples with a well-defined protocol, possibly using pre-prepared kit as done in some field studies.

While standard cytogenetic assays require days to complete, speed and throughput of the dicentric assay could be adapted for mass casualty triage (Lloyd 2000; Voisin 2001; Prasanna 2003). Faced with an urgent need for rapid results, clinical triage can be accomplished by scoring as few as 20 metaphase spreads per subject, compared with the typical 500 to 1000 spreads scored in routine analyses for estimating dose. For example, Lloyd (1997), after studying lymphocyte chromosome damage in 10 of the 13 severely irradiated Chernobyl victims, suggested that the frequency of metaphase spreads without dicentric aberrations can be used to identify patients suitable for cytokine therapy versus bone-marrow transplantation. In addition, sample processing throughput of cytogenetic laboratories can be increased by using robotic instruments, metaphase harvesters and spreaders, etc. Commercially available laboratory information management systems (LIMS) can be customized for dealing with the data and sample management challenges inherent in requests to process large quantities of samples for dose assessment. However research is needed to determine whether cytogenetics will have the necessary sensitivity (1 Gy) to detect clinically significant doses when applied in an emergency situation to large populations. At present, to deal with such a situation, multiple laboratories with common methods and calibrations will likely be needed to meet throughput, speed and sensitivity requirements.

Other approaches have been explored as well including the use of somatic null mutations at the glycophorin A locus on the surface of blood erythrocytes, micronucleus assay, and measurement of premature chromosome condensation, PCC and all have been found to be reliable indicators of exposure over a broad dose range (0.25 to 8 Gy) in the laboratory with high doses of ionizing radiation but with poor dosimetric discrimination at lower doses (Bigbee et al., 1997; Gray and Pinkel., 1994; Jones et al., 2001; Brown et al., 1997; Tawn et al., 2003; Bedford and Dewey, 2002; Durante 1996; Kanda 1999). Variations of the PCC assay (Prasanna, 2000) may provide dose estimates in less than 24 hours for relatively high doses of ionizing radiation, but still require validation.

In the last decades, the use of fluorescence *in-situ* hybridization (FISH) to label specific chromosomes has allowed the easy detection of chromosome translocations, which can persist for decades after exposure (Lucas, 1992). Translocations have played a fundamental role in determining the radiation

dose received by individuals exposed during the Chernobyl nuclear accident (Moore et al., 1997; Jones et al., 2001). Translocations can provide a very precise assessment of radiation dose with the proper calibration curve; however, the experimental method requires skilled personnel and expensive equipment. Additionally, the assay requires several days to a week to be completed and therefore cannot be used to obtain a fast estimate of the dose during the first few days after exposure when the information would be most critical for identifying victims of radiation accidents who could benefit the most by medical intervention.

Given cytogenetics current standing as the best accepted assay for radiation dose assessment and its limited throughput, we advocate that a national network of laboratories linked by standard methods and calibrations should be established to handle the potential surge in analysis needed in the event of an R/N event and this network should be integrated into the a national radiation protection program. Development of national biodosimetry network of reference laboratories could provide capacity needed to respond to a large scale or multi-site R/N incident.

In summation, research is needed to address the potential for more rapid cytogenetics, to develop standardized Food and Drug Administration approved assays and to develop a network of laboratories that can respond to a mass causality event. However, methods for its improvement should be encouraged and inter-laboratory variability in this bioassay needs to be characterized.

2. Dosimetry and Location-Based Dose Assessment

Physical dosimetry using pre-positioned dosimeters currently serves as a mainstay in the military, as well as all organizations in which personnel could be exposed to ionizing radiation. Personal dosimeters of this type exist in the form of film, thermoluminescent dosimeters, or track-etch devices.

Since radiation fields are typically determined during the early response of a radiological exposure, an individual's time and locations at the radiation incident scene should be recorded so that they can be used for dose reconstruction applications.

Dose estimates can be made through knowledge of the time an individual spent at a particular location if there is information on the radiation contamination in the environment for that area or on the exposure rate (and its rate of change) during the time the victim spends at the site of injury. Hence, information should be collected on the victim's whereabouts relative to the source of radiation such that their accumulated external dose can be

quickly estimated using simple hand-held calculating devices or from more complex models which would take much longer to determine.

The external dose received by an individual who has spent time in an area that has received contamination from a radiological dispersal device is proportional to the initial exposure rate they were subjected to and the time spent in that area.

Location and Time in Area

The integral dose received by exposed victims is important to determining the triage that is necessary; hence, information should be collected on the victim's whereabouts relative to the source of radiation such that their accumulated external dose can be quickly estimated.

The external dose received by a victim in the vicinity of an IND will be a sum of the instantaneous exposure from the prompt gamma rays and neutrons released by the explosion as well as the longer term exposure from radioactive debris and/or fallout. In contrast, the external dose received from a RDD will primarily be a function of the initial exposure rate¹ and the length of time spent in the area that received contamination. The prompt gamma and neutron dose will be extremely difficult to assess at time of triage without expert guidance on bomb yield coupled with measurements of fortuitous dosimeters at the site of exposure. In that case, it would be important to know the location of the exposed person, either relative to the site of the explosion, or relative to the site of the nearest measurement of exposure rate (or dose rate to air). However, for the case of continuing exposure from a ground contamination or due to a clandestine source, the critical information needed to assist initial dose assessment would include the exposure rate measured in air at least two points in time, the locations of the victim, and the length of time spent in the area where irradiation took place.

For example, when the exposure rate remained nearly constant during the time spent in the contaminated area, the dose to the whole body can be simply estimated:

$$D_T = \dot{X} t \text{ DCF}$$

where,

D_T = Whole body dose equivalent (Sv or rem), effective dose (Sv or rem), or absorbed dose (Gy or rad)

\dot{X} = exposure rate (Roentgen where $1 \text{ R S}^{-1} = 2.58 \times 10^{-4} \text{ C kg}^{-1} \text{ s}^{-1}$)

t = time (s) spent at location with exposure rate as described

DCF = exposure to dose conversion factor (Sv or rem, or Gy or rad, per R)

The conversion factor is about 0.8 for adults for most photon energies for rotational incidence (NCRP 1999).

The dose to a specific organ or tissue can also be estimated assuming that the exposure rate is nearly constant during the time spent in the contaminated area;

$$D_T = \dot{X} t (W/e)(D_T/K_a)$$

where,

D_T = tissue absorbed dose (Gy)

\dot{X} = exposure rate ($\text{C kg}^{-1} \text{ s}^{-1}$, where $1 \text{ R s}^{-1} = 2.58 \times 10^{-4} \text{ C kg}^{-1} \text{ s}^{-1}$)

t = time (s) spent at location with exposure rate as described

W/e = mean energy expended in air to form an ion pair $\approx 34 \text{ J/C}$

K_a = air kerma (Gy)

Note that values of D_T/K_a can be obtained from numerous sources, e.g., ICRP 74 (1996).²

If the exposure rate is changing substantially during the exposure period, then the dose to the person can be estimated from an integration of the dose rate over the exposure time:

$$D_T = \left[\int_{t_o}^{t_e} \dot{X}(t) dt \right] (W/e)(D_T/K_a)$$

where t_o is the time that exposure began, and t_e is the time that exposure ended. In the case of radioactive fallout, the radiation field decays approximately by the power law of $t^{-1.2}$:

$$X = \int_{t_o}^{t_e} \dot{X}_{TOA} \left(\frac{t}{TOA} \right)^{-1.2} dt = 5 \dot{X}_{TOA} TOA^{1.2} (TOA^{-0.2} - t_e^{-0.2})$$

where,

X is the integral expressed in milliRoentgens (mR) from TOA until t_e ,

¹Here *exposure rate* is used in the technical sense of the rate of ionization in air, i.e., $1 \text{ Roentgen s}^{-1} = 2.58 \times 10^{-4} \text{ C kg}^{-1} \text{ s}^{-1}$. Note that the dose to a person could also be determined from the dose to air.

²ICRP. International Commission on Radiological Protection. Conversion Coefficients for Use in Radiological Protection Against External Radiation. Report No. 74. Pergamon Press. 1996.

TOA is the time elapsed from the detonation until the arrival of the debris cloud (h),

X_{TOA} is the exposure rate at TOA (mR/h).

Since the time of measurement would undoubtedly be later than the time that exposure began, a simple decay correction can be from time of measurement, t_m , to the time when exposure began, t_o (again, assuming fallout from a nuclear detonation):

$$X_{TOA} = X_m \left(\frac{t_m}{t_o} \right)^{1.2}$$

If the exposure is due to a single radionuclide, then the equations can be modified for its half-life and energy.

Calculations such as those described here could be facilitated by use of pre-programmed hand instruments (calculators, Palm Pilots, etc.). In that case, the person who is responsible for the crude estimate of external dose (as described above) would need to input the following data: exposure rate (R/s) measured at a location relatively close to victim, the time of measurement, approximate time when exposure began, approximate time when exposure ended (i.e., when victim was removed).

If exposure rate measurements at the precise location of exposed victims are not available, measurements made nearby to the victim could be substituted with the restriction that both the measurement and the victim were both outside a building, or both inside.

In the case of a radiological terrorism event, it would seem that quick calculations via handheld devices would be possible, but would require that the outcome of that assessment be physically or virtually attached to the identity of the person, e.g., via a database including a photograph. During the chaotic situation that would follow such events, maintaining the dose assessment information with the victim will prove difficult.

3. Measurement of Radioisotope Contamination

The Centers for Disease Control is currently leading an effort to provide high-throughput bioassay of internal radioisotope contamination. While critical for medium- and long-term assessment, internalized radioisotope contamination dosimetry does not contribute to decisions made within the first 72 hours after initial exposure. Decorporation decisions will be driven

primarily by the long-term risk to the victim and to the availability of effective decorporation available to be brought to bear. In addition, contamination from nose swabs and clothing should be captured as part of an overall initial assessment, and estimation of internal contamination is important for long-term patient management.

If patients are few and there is an evident need to determine the total internal radiation dose, all body effluents should be collected for an extended time. Measurements of excreted radionuclides will provide information required to estimate the total internal body burden (NCRP 1980). Depending on the internally deposited radionuclide and its physicochemical characteristics, the collections may have to be made for months. For example, radionuclides with long radiological and biological half-times would need to be monitored longer than radionuclides with a short radiological or biological half-time. Radionuclides inhaled in relatively insoluble form would need to be monitored longer than more soluble forms due to the potentially extended residence in the lungs.

4. Pre-positioned Physical Dosimeters

Physical dosimetry using pre-positioned dosimeters currently serves as a mainstay in the military, as well as all organizations in which personnel could be exposed to ionizing radiation. Personal dosimeters of this type exist in the form of film, thermoluminescent dosimeters, or track-etch devices.

Measurement of neutron activation of sodium in blood or sulfur in hair is an approach that has been demonstrated in the laboratory for estimating prompt neutron dose. However the presence of high background radiation may make such measurements infeasible for use as a neutron dosimeter following an R/N event.

A new device, the Self-indicating Instant Radiation Alert Dosimeter or SIRAD™ (see www.jplabs.com for more information) is a low-cost, disposable dosimeter that is packaged similar to a credit card. This device presents the possibility of producing a low-cost, preposition civilian monitoring dosimeter. The sociological dimensions of wide distribution of such a device provide one of the greatest uncertainties for its deployment for use by the civilian population. Nevertheless, this type of technology, while relatively new, is a very exciting development for the field of personal dosimetry and should be evaluated for its value in a radiological or nuclear event.

C. Assessment of Emerging Dosimetry Technologies

1. Biological Measurements

A variety of biological materials can and have been used for diagnostic purposes in clinical medicine and forensics. Collection of certain biologic samples can incur some risks to the victims, but significant risks are primarily limited to tissue biopsies. These range in the risks and complexity of collection from hair and saliva for rapid safe and simple collection to sampling of internal tissues by biopsy which is complex and presents health risks to the casualty. We considered technologies that could be applied to any biological sample but expect that diagnostics will be limited in practice to samples that can be easily collected in a rapid fashion with little risk to the potential causality or responder. We also limited our evaluation to samples which responders are accustomed to dealing with and for which a supporting research literature base exists. We judged the most promising sample sources to be exfoliated cells, body fluids such as blood and saliva, and breath. Collection of tissues and other body fluids requiring risky, time consuming, complex collection procedures, are not generally handled by first responders, or have a limited supporting research base.

Molecular Markers in body fluids and tissues

Biomarkers are specific chemical or biological properties that can indicate a health-related process or outcome. They constitute molecules as diverse as proteins and small molecule metabolites. Biomarkers have been under intensive research for many decades and many reviews and books have been written on them and their use (Blakely et al., 2001; Mendelsohn, Mohr, and Peeters, 1998; Gledhill and Mauro, 1991 as examples). Biomarkers represent underlying changes in physiology which can arise from physical damage (cell lysis and the release of intracellular proteins into the circulation, oxidation by-products or DNA breakage), underlying changes in biochemistry (presence of new metabolites or changes in levels of key gene products), and / or changes in cellular composition of tissues. Biomarkers have been proposed for and used to diagnose the presence of infectious agents, to judge the damage caused by exposure to chemicals, to judge one's individual susceptibility to disease, to predict medical outcome and therapy, to measure organ system function, and to predict prognosis or health outcome for damaging exposures or disease. Likewise, it has been suggested by several expert panels that such markers could be useful in responding to an R/N incident particularly to enable rapid triage of at-risk populations (young, aged, those with significant health conditions) from potentially exposed individuals and to guide treatment and post-radiation victim care (NIH, 2005, JIWG, 2005; Trent Congressional Testimony at http://kyl.senate.gov/legis_center/subdocs/051104_trent.pdf).

The steadily increasing sophistication in our understanding of the early biochemical responses of irradiated cells and tissues provides the opportunity for developing mechanism-based biosignatures of exposure (Woloschak & Paunesku, 1997; Fornace et al., 1999; Tusher et al., 2001). Compelling breakthroughs have been made in the technologies for genome-scale analysis of cellular transcriptional and proteomic profiles (Chee et al., 1996; Lockhart et al., 1996; Lipshutz et al., 1999; Jain, 2002; Kukar et al., 2002; Issaq et al., 2003; Krieg et al., 2004), in the quantitation of biomolecular signatures, and in advanced statistical and bioinformatics methods to analyze large biological data sets (Dudoit et al., 2000; Werner, 2001; Peterson, 2002; Peterson, 2003). There have also been major strides in the mechanistic understanding of the early events in DNA damage and radiation damage products, as well as in the cellular pathways that lead to radiation injury (Thompson & Schild, 2001; Burma & Chen, 2004; Fernet & Hall, 2004; Kurz & Lees-Miller, 2004; Meek, 2004).

New research with genomic- and proteomic-wide tools is showing that within minutes to hours after exposure to ionizing radiation proteins are modified and activated, and large-scale changes occur in the gene expression profiles involving a broad variety of cell-process pathways (Amundson et al., 1999; Park et al., 2002; Kang et al., 2003; Yin et al., 2003). High-throughput gene expression profiling in human peripheral blood lymphocytes irradiated *ex vivo* and other human cells have identified several genes, such as GADD45 and CDKN1A, whose expression increases as a function of the ionizing Radiation dose (Amundson, 1999; Blakely et al., 2001; Kang et al., 2003). Transcriptional changes should correlate with changes in protein expression, and a recent survey of the literature has identified several proteins that provide evidence of exposure over a range of dose and time.

A review of the literature suggests that there are presently approximately 90 known proteins that show changes in expression or undergo post-translational modifications after exposure to ionizing radiation. Some of these change in a dose dependent fashion although there is limited data on the shapes of dose- and time-response curves. To date, most of these proteins (approx. 90%) were identified using *in vitro* tumor cell models and the majority of research has been with high doses of ionizing radiation (> 4Gy). Few human- or animal-based studies have been reported and limited validation of the use of molecular biomarkers for radiation injury assessment has taken place in clinical populations although some validation of the value of molecular markers for judging biological dose for ionizing

radiation is now being published and appears promising (Leslie, 1992; Becciolini, 2001). Serum amylase, for example, is a case where clinical assays presently exist and where there is data suggesting radiation responsiveness.

Although more research is needed, the wealth of information generated by these studies provides the foundation for developing mechanism-based biosignatures of exposure that correlate with the timing and dose of radiation exposures. In addition, the rapid explosion of proteomic/genomic/metabolomic technologies and innovations and their application to the systematic characterization of the proteomic, genomic and metabolomics profiling of healthy human tissues and serum (Tirumalai et al., 2003), provide baseline references for identifying early biomarkers of radiation exposure and of tissue-specific damage. At present, even though there are significant limitations in extrapolating the value of the nucleic acid, metabolite or proteins discussed above to the human R/N threat scenarios, a set of proteins or mRNA targets do seem to offer potential for use as biomarkers (see Table 5).

Recognition of the gap in available early and rapid technologies for radiation dose assessment has accelerated research into the applicability of molecular markers as indicators of radiation dose. However, at the present time, this technology is in its infancy. Research into the discovery of markers indicative of radiation exposure is primarily being carried out in academic institutions and government laboratories. No commercial assays have been developed or marketed and there presently is little effort in the industrial sector to develop such assays for radiation dosimetry or triage. Likewise little R&D funding has been directed towards development of commercial assay concepts and prototypes (although the Department of Defense and the National Institutes of Health will fund some centers and increase spending in the near term to conduct such research). Research is needed to understand how these markers respond to different types of radiation, how these markers relate to known clinical or biologically relevant effects and dose rate effects. There is a critical need to understand the normal expression range of potential radiation markers in healthy people as well as groups with pre-existing health conditions.

Additionally, an understanding of the time and dose kinetics and effects of other confounding factors such as age, gender, and genetic background needs to be understood. The value of single parameter versus multi-parameter signatures should also be evaluated. Analytic models based on quantitative data using various model systems are required. An understanding of sensitivity and specificity of potential molecular markers is needed. Statistical methods to evaluate and interpret assay results needs development and validation. Research is also needed into judging the value of these biomarkers for indications of latent radiation responses even though initial efforts may focus on the diagnostic information for acute early-response.

While most research and technology development has so far centered on genomics and proteomics, other potential molecular classes could prove useful as indicators of radiation dose also and should be investigated. In particular research is beginning on small molecule metabolites, lipids, and glycosylated, biomolecules. National efforts in this regard can be significantly aided by international research efforts and experiences.

Breath Gas Analysis

Another promising area for biological measurement of radiation injury is breath analysis. The vast majority of tissue damage following irradiation results from the action of free radicals

Table 5. High-priority candidate radiation-responsive proteins for biomarker development.

Protein		
Priority Group	Symbol	Name
1	ATM	ataxia telangiectasia mutated
	H2AX	Histone 2AX
2	CDKN1A	cyclin-dependent kinase inhibitor 1A (p21, Cip1)
	DDB2	damage-specific DNA binding protein 2
	GADD45A	growth arrest and DNA-damage-inducible 45 alpha
	PCNA	Proliferating cell nuclear antigen
	CCNB1	cyclin B1
3	BLM	Bloom syndrome protein
	RPA1	replication protein A1
	Tp53	tumor protein p53
	CHK2	checkpoint kinase
	CDK4	Cyclin-dependent kinase 4
	CDKN2A	cyclin-dependent kinase inhibitor 2A (p16)
	ENO1	enolase 1
	ERP 29	similar to Protein disulfide isomerase A4 precursor

Proteins with data from more than one species are indicated in bold.

produced by the absorption of ionizing radiation. Free radical-induced damage is associated with the process of lipid peroxidation of omega-3 and omega-6 fatty acids (Sies 1997). End products of lipid peroxidation of polyunsaturated fatty acids are ethane and pentane. No other major endogenous sources of ethane and pentane are anticipated other than lipid peroxidation (Kharitonov and Barnes 1994).

Breath ethane generation was measured by Arterberry et al (1994) during clinical total body irradiation for treatment over a 4-day period. The largest changes in breath ethane occurred on day 2 and these changes were correlated with clinical manifestations of gastrointestinal side effects. Since the study by Arterberry et al (1994) several authors have explored more sensitive methods for measuring breath gasses. The study by Mueller et al (1998) evaluated breath analysis of exhaled air by mechanically ventilated patients using microwave energy desorption coupled with gas chromatography-flame ionization detection-mass spectrometry. Infrared laser spectroscopy was used by Basum et al (2003) who were able to detect in near real-time 500 ppt ethane. Other molecules are also present in breath and efforts have been made to explore their utility for disease diagnostics.

These studies suggest the possibility of breath analysis as a tool to support triage following an IND/RDD event. However, these gases are associated with a variety of medical conditions that may complicate future attempts to use breath analysis to estimate absorbed radiation dose. Research is needed on how well they relate to radiation dose.

Devices for Biological Indicators of Radiation Injury

A vast array of technologies is being developed and applied to researching biological indicators of disease and is being developed for use in diagnosis. Platforms have been developed for analysis of proteins, DNA/RNA, molecules in breath, small molecule metabolites, cells and others. These are generally based on DNA microarray, Polymerase Chain Reaction (PCR) based assays (PCR), protein array, multiplexed-antibody assays, lateral flow immunoassay (LFD), mass spectrometry, various chromatography's, spectroscopic analysis, image analysis, flow cytometry and SAGE (serial analysis of gene expression). A variety of companies have proprietary platforms for conducting these analysis including, as examples, Luminex for multiplexed antibody assays; Affymetrix for DNA microarrays; Litron Laboratories for flow cytometry-based methods for cytogenetic

damage; Loats Associates for automated micronucleus assay; and Metabolon for metabolic pathway mapping. While many technologies have been developed, none are available for molecular diagnostics of radiation injury (see Baker, 2005) and few are available for cell analysis.

The simplest promising device that has applications for radiation biodosimetry triage is the lateral flow immunoassay device (LFD). LFDs are a common diagnostic assays employed in clinical laboratories. Most people are aware of the use of this format in over-the-counter pregnancy tests. Laboratory tests are available to the clinician for fertility, pregnancy, infectious disease, veterinary, and food safety applications, and new ones are being developed at a steady rate (eg, Quach et al., 2002, O'Keefe et al., 2003, Slinger et al. 2004, Cazacu et al., 2004). In addition, the US military uses this format in the field to detect biological warfare agents with their Hand Held Assays (HHAs). These can be run by hand or employed in automated systems. In 2004, the US military produced over 9 million HHAs. The anthrax letter that was sent to Senator Daschle was tested on site with an HHA which shut down the congressional mail and prevented the letter addressed to Senator Leahy from being opened.

As mentioned, while a variety of technologies, tools and methodologies have been developed to discover, characterize and analyze proteomic, metabolomic, and genomic, markers for diseases, there is no commercial assay available for radiation dose estimation and limited evidence of development in this area. There are few patents for radiation biodosimetry diagnostics, few awarded research proposals, and some requests for proposals in this area from the Department of Defense and the National Institutes of Health. However, since significant industrial effort is being devoted to development and marketing of diagnostics for other health-related conditions (cancer, infectious disease, etc) it should be possible to rapidly develop and commercialize radiation dosimetry tools once the basic research finds and validates relevant molecular indicators of radiation exposure. Research investment is needed in exploring the development of such tools specifically for radiation biodosimetry, concepts of operation and their application.

2. Physico-Chemical Measurements

We have identified several techniques that can potentially use changes in physical and chemical attributes of tissue and/or other materials that people carry as a means to estimate radioaction dose. Prior investment in attempting to capitalize on these

characteristics has been uneven and therefore it is difficult to provide inter-comparisons with respect to potential. For example, optical stimulation of luminescence (OSL) is a well-defined science supporting commercial dosimetry systems for workers in nuclear facilities. But the use of teeth or bone as dosimeters represents additional technological challenges. Electron parametric resonance (EPR) of tooth enamel, on the other hand, has been used essentially for retrospective dose estimation in support of epidemiologic studies but currently requires an extracted tooth, an invasive procedure not likely acceptable in the first hours after a large terrorist event. We present concepts below that vary considerably in underlying technologies. While there certainly are additional concepts, we will focus on the following:

- Luminescence
 - Teeth and Bone
 - Fortuitous Dosimeters
- Electron Parametric Resonance
- Breath Analysis
- Ultrasound

Luminescence

Estimating dose from physical measurements has been under investigation for many years. Dose response luminescence of a wide variety of natural and manufactured materials has been studied since the early decades of the 20th century. Initial experiments concentrated on prompt phosphors and photoluminescence, however technical improvements in fine control of thermal profiles led to the development of thermoluminescence (TL) as a reliable means of detection of radiation doses absorbed by a variety of natural and manufactured wide-gap insulators. Understanding of the dose response TL behavior of natural materials, primarily quartz and feldspar, was given a tremendous boost by a key group at Oxford University in the 1960's to 1980's (Aitken, 1985). Although their focus was the chronology and authentication of archaeological objects, the basic research carried out by members of the group led to methodologies suitable for the detection of very low absorbed radiation doses and therefore to retrospective dosimetry.

The recognition that exposure to sunlight of natural geological deposits results in a depletion of their TL signal led to the

invention of optical dating (Huntley et al., 1985). In this technique, dose response luminescence is stimulated optically rather than thermally, as in TL. OSL, in which stimulation is provided by infrared or visible photons rather than by heat was quickly recognized as providing a number of advantages over TL. For example, with a short pulse of stimulating light, the trapped charge population may be sampled rather than completely erased as it is in a TL measurement. Thus different wavelengths of light, tailored for optimal luminescence response in different minerals may be selected; a wide or narrow detection region is achievable with appropriate stimulating photons or with pulsed rather than continuous stimulation; and a high concentration of stimulating photons permits the detection of luminescence from an aliquot as small as a single sand-sized grain of quartz with a mass of ~2 μg . In addition, transmittance of both stimulating photons and emitted luminescence via fiber-optic cables is easily achievable, thus permitting a degree of flexibility and optimization of instrumentation design simply not possible with TL. OSL may also be detected simultaneously with TL or, if the sample is being continuously irradiated, with radioluminescence (RL). Many of these potential advantages have been discussed and implemented within the past two decades (Aitken, 1998; Bøtter-Jensen et al., 2003) but primarily as a laboratory, rather than a field technique.

Optical Stimulation of Teeth and Bone

A portable OSL dosimetry instrument that could be used on an intact person has been suggested by Godfrey-Smith and Pass (1997). The key advantage of such an instrument is that it would use non-ionizing photons rather than electron resonance to stimulate luminescence (Huntley et al., 1985), and therefore any risks associated with its use should be no more dangerous (in principle) than shining a strong light into a person's mouth.

The key observation of the initial investigation of the OSL properties of tooth enamel is that both infrared and visible green photons are capable of stimulating luminescence, and that the dose response is detectable in both a broadband visible region (when stimulated with infrared photons) and in the near-ultraviolet (when stimulated with green photons). Godfrey-Smith and Pass (1997) also showed that signal response is stronger in non-deproteinated tooth enamel versus deproteinated enamel. A dose of 15 Gy should be readily detectable in non-deproteinated enamel: i.e., whole teeth, with an S/N ratio of 3, with no changes in present instrumentation. One may deduce from this that steps toward the optimization of stimulating wavelength, its incident intensity, spectral width of

the detection band, and the tooth-to-detector geometry should make the detection of much lower (10X) doses readily achievable. Such optimization could bring the lower limit of detection to approximately 0.25-0.5 Gy.

Optical Stimulation of Fortuitous Dosimeters

Members of the public do not carry calibrated radiation dosimeters like those provided to radiation workers, but there are a number of common materials often in their possession or nearby that can serve as dosimeters for evaluating the degree of radiation exposure from an incident. Radiation dose from X-rays, γ -photons and β -particles can be measured using diamonds and other semi-precious stones in jewelry; semiconductor components in cell phones, personal digital assistants and car keys, quartz in watches and watch faces, and even tooth enamel. All the previously listed materials potentially store energy from ionizing radiation as unpaired electrons trapped in elevated energy states. These unpaired electrons can be detected and measured a number of ways: – by EPR, TL, and OSL – to determine the radiation dose. Alpha (α) particles that could originate from uranium and transuranic radioisotopes and neutrons from nuclear devices can be detected in glass and many plastics, including those used in watch covers and eyeglass lenses after etching with a strong base solution. However calibration of measurement to predict the actual dose received by a person will likely present difficulties. Other radiation-sensitive materials in buildings and soil can be used to determine isodose curves around the radiation event. Quartz, used widely for radiation damage dating of archaeological artifacts, is ubiquitous in soil and building materials, and its man-made counterpart is the principal component of fiber-optic cable. Even common table salt can serve as a radiation dosimeter.

Determining the radiation dose from a fortuitous (un-calibrated) dosimeter material subsequent to its exposure requires two steps. The first step involves measuring the “as-found” signal from the material. The second step requires exposing the sample to a known radiation field and measuring the additional response. The sample’s radiation sensitivity, from the second step, is then used to evaluate the “as-found” dose from the first step. This practice was used in the reconstruction of doses to A-bomb survivors with, for example, tile and brick, heated to produce TL (RERF, 1983). Stimulation of light from materials using both thermal and light stimulation is in use worldwide in geologic studies to assist in the dating of events and materials (Godfrey-Smith and Pass, 1997). Development of a useful

technology will require identification of common items carried by people that can serve as fortuitous dosimeters, determination of which have the sensitivity to be of use in post-exposure injury assessment, and development of procedures for readout and calibration.

The phenomenon of TL was first observed in diamond by Robert Boyle, who reported to the Royal Society in London on October 28, 1663 (Becker, 1975). Diamond films made using the chemical vapor deposition process, with various impurities to enhance radiation response, have been studied and shown to be effective dosimeter materials for radiation doses from 0.8 Gy to 3 kGy (Barboza-Flores et al, 2004). Natural diamond has its own impurities (responsible for color and other qualities), and the radiation sensitivity for a particular gemstone would be determined a posteriori as part of the dosimetric analysis, as noted above. A variety of other minerals can be used for radiation dosimetry, including some semi-precious gems like sphene and epidote. The fundamental TL properties of these minerals have been studied at very high doses (1 - 3 kGy), but the range of radiation sensitivities needs to be determined (Khalifa, Khalifa and Durrani, 1986).

Natural quartz and its man-made analog used extensively in optical fibers provide another source of fortuitous dosimeters, both for evaluating radiation doses to incident victims and for establishing radiation isodose curves in the area surrounding a radiological event. Natural quartz is ubiquitous in nature and can be found virtually wherever there is dirt except in coral-based soils. Grains of sand from shoe soles, pants cuffs and pockets, city streets, and plant leaves provide a record of dose from a radiological event (Khan and Delincée, 1995). Fiber-optic strands are excellent radiation dosimeters from 0.1 Gy to several kGy and are associated with computer networks and cable service in many buildings (Espinosa et al, 2004). Optical fibers will probably be available for analysis of a radiological event, since such events are most likely to occur in areas with a highly developed infrastructure, either because of commercial use of the material involved in the event, or because of terrorist targeting.

Common table salt is also an excellent radiation dosimeter. Impurities such as potassium, calcium, magnesium, iron, copper and silver create defects in the salt crystal structure that provide sites where orbital electrons promoted by interaction with ionizing radiation become trapped and can be measured by EPR, TL or OSL. Radiation doses from 0.01 - 1,000 Gy have been

measured using untreated table salt (Kaibao et al, 1986). Any building with a cafeteria or break area, food vendors on the street and packages of salted snacks from the vicinity of a radiological event provide a wealth of material for radiation dosimetry.

The number of α particles absorbed following dispersion of uranium or transuranic materials, or neutrons from detonation of a nuclear device, is possible using a variety of glass or plastic materials, including picture glass, eyeglass lenses, and compact disks (Fleischer, 2002). Neutrons interact with uranium impurities in glass, causing them to fission and leave tracks (damage in the glass structure from energetic charged particles released in the fission event) that can be developed to visible size and counted. Polymer chains that make up plastic materials are damaged by charged particles from alpha emitters on the surface or from neutron interactions with atoms in the plastic itself. These can be etched with a caustic solution to enlarge the damage sites to visible size. The number of damage sites reflects the total particle fluence (source strength), and certain characteristics of the tracks' geometry can be used to provide energy spectra, useful in identifying the source material (Phillips et al, 2004) and for estimating dose.

Optical Stimulation Instrumentation

Several OSL instrumentation systems currently exist, some of which are commercially available (Bøtter-Jensen et al., 2003). All current commercial systems, however, are designed for bench-top laboratory use only; none are portable. Most extensively used are those systems designed for automated, multiple-sample analysis, primarily for geological or archaeological dating (e.g. those systems manufactured by Riso National Laboratory or by Daybreak Inc). Others are designed for personnel dosimetry application, such as the InLight™ system manufactured by Landauer Inc. All of these systems,

however, are designed to have the sample (or dosimeter) placed inside the apparatus and none is appropriate for field application. Polf et al. (2004) and Gaza et al. (2004) describe a fiber-optic system designed to measure absorbed doses by $\text{Al}_2\text{O}_3:\text{C}$ OSL dosimeters. Overall design is based on similar systems described earlier by Justus et al. (1999) and Huston et al. (2001). Similar apparatus is also described by Anderson et al. (2003). The primary application for each of these systems is *in-vivo* radiation dosimetry during radiotherapy (external beam and/or brachytherapy) and the OSL measurement scheme in these applications is by continuous-wave stimulation (CW-OSL). A similar system is described by Klein et al (2004) for environmental dosimetry. Since the goal of the latter work is to measure low level environmental doses the Klein et al. apparatus is designed for optimum sensitivity, and uses pulsed OSL (POSL) rather than CW-OSL. POSL measures the OSL signal between stimulation pulses rather than during the stimulation and leads to a high signal-to-noise ratio.

Electron Paramagnetic Resonance

The development of the theory and instrumentation of electron spin resonance paralleled that of TL and OSL. ESR (also called EPR, electron paramagnetic resonance) has made it possible to detect radiation doses absorbed by a very wide variety of organic as well as inorganic materials. The inorganic hydroxyapatite component of tooth enamel and bone is not only a well known natural dosimeter, it is also unique amongst all living tissues in its ability to retain the signal from absorbed radiation dose on time scales that are sufficiently long to be of use in human dosimetry's risk assessment. (Other tissues such as blood provide evidence of radiation exposure, but suffer from a rapid disappearance of detectable changes from absorbed dose.) For this reason, attempts to develop instrumentation for *in vivo* ESR measurement of dose to teeth in humans have been recognized as having potential applications (Ikeya and Ishii, 1989; Yamanaka et al., 1993). Unfortunately, these early efforts resulted in microwave burns to volunteers. Although progress is being made in this regard, most recently reported data indicate

that applications to human teeth are still at the *ex vivo* stage, although the instrumentation is suitable for *in vivo* applications with research animals (Miyake et al., 2000; Swartz et al., 2004a, 2004b).

Further emerging development work, using smaller magnetic fields (smaller magnet systems) could lead to practical and safe *in vivo* dose assessment in teeth and bone. The goal would be to develop a portable instrument to rapidly assess clinically significant exposures in the field.

Ultrasound

Medical injury from a terrorist event (IND, RDD) is likely to involve thermal trauma in addition to radiation injury (combined injury). A high frequency ultrasound technique has been developed to function as a clinical tool to distinguish partial-thickness from full-thickness thermal burns (Roswell, Goans and Cantrell, 1977; Goans, Cantrell and Meyers, 1977; Cantrell, Goans and Roswell, 1978; Goans and Cantrell, 1978). Electrical and thermal burns represent a class of traumatic injury whose severity is difficult to diagnose through conventional clinical techniques. In many cases involving burns, the prognosis for patient survival is dependent upon an early and precise knowledge of both the magnitude of injury and of the depth of burn. This technique could be extended to analyze radiation-induced injury. The method is intended to use a conventional off-the-shelf medical ultrasound unit with an adjunct computer-driven analyzer.

Because most hospitals utilize ultrasound routinely, the potential use of ultrasound to estimate dose also has significant merit as an adjunct to fortuitous dosimeters (discussed above) or possibly internal dose estimates based on nasal swabs, among others. The concept has been proven in principle by its ability to evaluate burn damage (Goans and Cantrell, 1978). Like

fortuitous dosimeters, that may be readable with readily available equipment, ultrasound analysis may also provide invaluable assistance in the identification of people who have received radiation exposures that were below a level that could be detected by other means. This is of great importance if many people are assumed to be significantly exposed and medical triage must be administered.

A conventional ultrasound pulse-echo unit (5-30 MHz) was modified so that necrotic tissue at shallow depths (< 5 mm) from the skin surface could be resolved. Resolution of soft-tissue damage is less than 0.2 mm. This requirement was necessary so that deep dermal damage could be separated from epidermal necrosis and from thermal injury near the subcutaneous fat layer. The technique received a patent through the Oak Ridge National Laboratory and the Atomic Energy Commission (AEC) and was subsequently licensed into the private sector (Goans et al, 1978) where the technique has matured with improvement in ultrasound technology (Adams, Murphy, Gillespie and Roberts, 2000; Bauer and Sauer, 1989). The use of pulse-echo ultrasound is a stable clinical technique for ascertaining burn depth (Goans 1985). In that report, data were presented that show that the depth of necrotic tissue remains constant with time during a 12 day period after the burn was initiated.

Two pilot studies indicate that both pulse-echo ultrasound and standard B-scan ultrasonic imaging are sensitive to high-level radiation-induced cutaneous damage (Goans, 2005). Ultrasonic analysis of radiation burns appears to be much more complicated than for thermal burns because what is likely being measured is early vascular damage and vascular leakage. However, the sensitivity of the technique for measuring pathology is at least as great for radiation injury as for thermal injury. In fact, it may actually be more sensitive. Statistically significant changes ($p < 0.05$) in the magnitude of the reflected ultrasound spectrum have been noted less than 30 min post-irradiation. While promising, research is needed to better understand how to use ultrasound in a field setting and what its ultimate capabilities are.



References

- Adams, T.S., Murphy, J.V., Gillespie, P.H., and Roberts, A.H., 2000. "The use of high-frequency ultrasonography in the prediction of burn depth," *J. Burn Care Rehabil.* **21**(4), 333–338.
- Aitken, M.J., 1985. *Thermoluminescence Dating*. New York: Academic Press.
- Aldrich, J.E., and Pass, B., 1986. "Dental enamel as an *in vivo* radiation dosimeter: separation of the diagnostic x ray dose from the dose due to natural sources," *Rad. Prot. Dosim.* **17**, 175–179.
- Amundson, S.A., Bittner, M., Chen, Y., Trent, J., Meltzer, P., and Fornace, A.J.J., 1999. "Fluorescent cDNA microarray hybridization reveals complexity and heterogeneity of cellular genotoxic stress," *Oncogene* **18**, 3666–3672.
- Andersen, C.E., Aznar, M.C., Bøtter-Jensen, L., Brack, S.S., A.J., Mattsson, S., and Medin, J., 2003. "Development of optical fibre luminescence techniques for real time *in vivo* dosimetry in radiotherapy," *Standards and Codes of Practice in Medical Radiation Dosimetry* (Proceedings of the International Symposium Vienna, 2002), Vol. 2, IAEA, Vienna, 353–360.
- Arterbery, V.E., Pryor, W.A., Jiang, L., Sehnert, S.S., Foster, W.M., Abrams, R.A., Williams, J.R., Wharam, M.D. Jr., and Risby, T.H., 1994. "Breath ethane generation during clinical total body irradiation as a marker of oxygen-free-radical-mediated lipid peroxidation: a case study," *Free Radic. Biol. Med.* **17**(6), 569–576.
- Awa, A.A., 1983. "Chromosome damage in atomic bomb survivors and their offspring—Hiroshima and Nagasaki," *Radiation-Induced Cytogenetic Damage in Man*, T. I. A. M. Sasaki. New York: Alan R. Liss, 433–453.
- Baker, M., 2005. "In biomarkers we trust?" *Nature Biotechnol.* **23**, 297–304.
- Barboza-Flores, M., *et al.*, 2004. "Optically stimulated luminescence dosimetry on CFD diamond films," *Phys. Stat. Sol. (A)* **201**(11), 2548–2552.
- Basum, G., Dahnke, H., Halmer, D., Hering, P., and Murtz, M., 2003. "Online recording of ethane traces in human breath via infrared laser spectroscopy," *J. Appl. Physiol.* **95**, 2583–2590.
- Bauchinger, M., Schmid, E., and Braselmann, H., 1986. "Cell survival and radiation induced chromosome aberrations. II. Experimental findings in human lymphocytes analysed in first and second post-irradiation metaphases," *Radiat. Environ. Biophys.* **25**, 253–260.
- Bauer, J.A., and Sauer, T., 1989. "Cutaneous 10 MHz Ultrasound B Scan allows the determination of burn depth," *Burns Incl. Therm. Injury* **15**(1), 49–51.
- Becciolini, A., Porciani, S., Lanini, A., Balzi, M., and Faraoni, P., 2001. "Proposal for biochemical dosimeter for prolonged space flights," *Physica Medica* **17**, 185–186.
- Becker, K., 1975. *Solid State Dosimetry*. Ohio: CRC Press.
- Bedford, J.S., and Dewey, W.C., 2002. "Historical and current highlights in radiation biology: has anything important been learned by irradiating cells?" *Radiation Research* **158**, 251–291.
- Bender, M.A., and Gooch, P.C., 1966. "Somatic chromosome aberrations induced by human whole-body irradiation: the "Recuplex" criticality accident," *Radiat. Res.* **29**, 568–582.
- Bender, M.A., Awa, A.A., Brooks, A.L., Evans, H.J., Groer, P.G., Littlefield, L.G., Pereira, C., Preston, R.J., and Wachholz B.W., 1988. "Current status of cytogenetic procedures to detect and quantify previous exposures to radiation," *Mutat. Res.* **196**, 103–59.
- Benderitter, M., Durand, V., Caux, C., and Voisin, P., 2002. "Clearance of radiation-induced apoptotic lymphocytes: *ex vivo* studies and an *in vitro* co-culture model," *Radiat. Res.* **158**, 464–474.
- Bigbee, W. L., Jensen, R. H., Veidebaum, T., Tekkel, M., Rahu, M., Stengrevics, A., Auvinen, A., Hakulinen, T., Servomaa, K., Rytomaa, T., Orams, G., and Boice, J.D., 1997. "Biodosimetry of Chernobyl cleanup workers from Estonia and Latvia using the glycophorin *a in vivo* somatic cell mutation assay," *Radiat. Res.* **147**, 215–224.
- Blakely, W.F., Prasanna, P.G., Grace, M.B., and Miller, A.C., 2001. "Radiation exposure assessment using cytological and molecular biomarkers," *Radiat. Prot. Dosimetry* **97**, 17–23.

- Bøtter-Jensen L., McKeever S.W.S., and Wintle A.G., 2003. *Optically Stimulated Luminescence Dosimetry*. Amsterdam: Elsevier.
- Brooks, A.L., 1999. "Biomarkers of exposure, sensitivity and disease," *Int. J. Radiat. Biol.* **75**, 1481–1503.
- Brooks, A.L., 2001. Biomarkers of exposure and dose: state of the art. *Radiat. Prot. Dosimetry*, **97**, 39–46.
- Brown, J.M., Hertveldt, K., Philippe, J., Thierens, H., Cornelissen, M., Vral, A., and De Ridder, L., 1997. "Flow cytometry as a quantitative and sensitive method to evaluate low dose radiation induced apoptosis *in vitro* in human peripheral blood lymphocytes," *Int. J. Radiat. Biol.* **71**, 429–433.
- Burma, S., and Chen, D.J., 2004. "Role of DNA-PK in the cellular response to DNA double-strand breaks," *DNA Repair* **3**, 909–918.
- Cantrell, John H., Jr., Goans, R.E., and Roswell, R.L., 1978. "Acoustic impedance variations at burn-nonburn interfaces in porcine skin," *J. Acoust. Soc. Am.* **64**, 731.
- Cerveny, T.J., 1989. "Treatment of internal radionuclide contamination" in *Textbook of Military Medicine Part I: Warfare, Weaponry, and the Casualty Volume 2, Medical Consequences of Nuclear Warfare*. Office of the Surgeon General, Department of the Army, Col. R. Zajtcuk, R.I. Walke, and T.J. Cerveny, Eds. (available online at <http://www.afrii.usuhs.mil/www/outreach/mmresources.htm>).
- Cerveny, T.J., and Cockerham, L.G., 1986. "Medical management of internal radionuclide contamination," *Medical Bulle. U.S. Army, Europe* **43**(7), 24–27.
- Chee, M., Yang, R., Hubbell, E., Berno, A., Huang, X.C., Stern, D., Winkler, J., Lockhart D.J., Morris, M.S., and Fodor, S.P., 1996. "Accessing genetic information with high-density DNA arrays," *Science* **274**, 610–614.
- Cologne, J.B., and Preston, D.L., 2000. "Longevity of atomic-bomb survivors," *Lancet*, **356**, 303–307.
- Conklin, J.J., Walker, R.L., and Hirsch, E.F., 1983. "Current concepts in the management of radiation injuries and associated trauma," *Surg. Gynecol. Obstet.* **156**, 809–829.
- Cosgriff, J.H. Jr., 1987. "Guidelines for the emergency management radiation injury," *Int. Med. Spec.* **8**, 170–180.
- Dainiak, N., 2002. "Hematologic consequences of exposure to ionizing radiation," *Exp. Hematol.* **30**, 513–528.
- Dainiak, N., Waselenko, J.K., Armitage, J.O., MacVittie, T.J., and Farese, A.M., 2003. "The hematologist and radiation casualties," *Hematology* (Am. Soc. Hematol. Educ. Program), 473–496.
- Davis, C.J., 1999. "Nuclear blindness: an overview of the biological weapons program of the former Soviet Union and Iraq," *Emerg. Infect. Dis.* **5**, 509–512.
- Dudoit, S., Yang, Y.H., Callow, M., and Speed, T.P., 2000. *Statistical Methods for Identifying Differentially Expressed Genes in Replicated cDNA Micro array Experiments*. Berkeley, CA: University of California.
- Durakovic, A., 1987. "Internal contamination with medically significant radionuclides," in *Military Radiobiology*, J.J. Conklin and R.I. Walker, Eds., Orlando, FL: Academic Press, 241–264.
- Durante, M., George, K., and Yang, T.C., 1996. "Biological dosimetry by interphase chromosome painting," *Radiat. Res.* **145**, 53–60.
- Durbin, P.W., 1972. "Plutonium in man: A new look at the old data," in *Radiobiology of Plutonium*, B.J. Stover, W.S.S. Jee, and J.S. Montague, Eds., J.W. Press, Salt Lake City, UT, Department of Anatomy, University of Utah Printing Service: 469–530.
- Espinosa, G., *et al.*, 2004. "Commercial optical fiber as TLD material," *Proceedings of the 14th International Conference on Solid State Dosimetry*, New Haven CT, June 27–July 2, 2004 (to be published in *Radiation Protection Dosimetry*).
- Fernet, M., and Hal, L.J., 2004. "Genetic biomarkers of therapeutic radiation sensitivity," *DNA Repair*, **3**, 1237–1243.
- Fleischer, R. L., 2002. "Serendipitous radiation monitors," *Am. Scientist* **90**, 324–331.
- Fliedner, T.M., Friesecke, I., and Beyrer, K., 2001. *Medical Management of Radiation Accidents: Manual on the Acute Radiation Syndrome*. Oxford: British Institute of Radiology.

- Fornace, A.J., Amundson, S.A., Bittner, M., Myers, T.G., Meltzer, P., Weinstein, J.N., and Trent, J., 1999. "The complexity of radiation stress responses: analysis by informatics and functional genomics approaches," *Gene Expr.* **7**, 387–400.
- Gaza, R., McKeever, S.W.S., Akselrod, M.S. Akselrod, A., Underwood, T., Yoder, C., Anderson, C.E., Aznar, M.C., Marchmann, C.J., and Bøtter-Jensen, L., 2004. "A fiber dosimetry method based on OSL from $\text{Al}_2\text{O}_3\text{:C}$ for radiotherapy applications," *Radiat. Meas.* **38**(4–6), 809–812.
- George, G.W., Cieslak, T.J., Pavlin, J.A., and Eitzen, E.M., 1997. "Biological warfare: a historical perspective," *JAMA* **278**, 412–417.
- Glasstone, S., and Dolan, P.J., Eds., 1977. *The Effects of Nuclear Weapons*. Third edition. U.S. Department of Defense and Department of Energy.
- Gledhill, B.L., and Mauro, F., Eds., 1991. *New Horizons in Biological Dosimetry*. New York: Wiley-Liss.
- Goans, R.E., 1985. "Quantitative assessment of burn wound progress," *Maryland Med. J.* **34**, 576.
- Goans, R.E., *et al.*, *Ultrasonic Technique for Characterizing Skin Burns*, U.S. Patent 4,080,960 (May 28, 1978).
- Goans, R.E., and Cantrell, J.H., Jr., 1978. "Ultrasonic characterization of thermal injury in deep burns," in *Proceedings of the Third International Symposium on Ultrasonic Imaging and Tissue Characterization*. National Bureau of Standards.
- Goans, R.E., Cantrell, J.H., Jr., and Meyers, F.B., 1977. "Ultrasonic pulse echo determination of thermal injury in deep dermal burns," *Med. Phys.* **4**, 259.
- Goans, R.E., and Wald, N., 2005. "Radiation accidents with multiple organ failure in the United States," in *Proceedings of the Advanced Workshop on Multi-organ Failure in Radiation Accidents*. Ulm, Germany: University of Ulm. Accepted by *Brit. J. of Rad.*
- Goans, R.E., 2005. Presented at the 2005 Health Physics Midyear Symposium in New Orleans, LA.
- Goans, R.E., 2004. "Medical lessons from U.S. and international radiation accidents," Chapter 21. *Proceedings of the 2004 Health Physics Society Summer School*. in Medical Physics Publishing.
- Godfrey-Smith, D. I., and Pass, B.A., 1997. "A new method of retrospective biophysical dosimetry: optically stimulated luminescence and fluorescence in dental enamel," *Health Phys.* **72**(3), 390–396.
- Gray, J.W., and Pinkel, D., 1994. "Fluorescence *in situ* hybridization in cancer and radiation biology," *Rad. Res.* **137**, 275–289.
- Gusev, I.A., Guskova, A.K., and Mettler, F.A., (2001). *Medical Management of Radiation Accidents*, New York: CRC Press.
- Hayata, I., Kanda, R., Minamihisamatsu, M., Furukawa, M., Sasaki, M.S., 2001. "Cytogenetic dose estimation for 3 severely exposed patients in the JCO criticality accident in Tokaimura." *J. Radiat. Res.* **42**, S149–155.
- Huntley, D.J., Godfrey-Smith, D.I., and Thewalt, M.L.W., 1985. "Optical dating of sediments," *Nature* **313**(5998), 105–107.
- Huston, A.L., Justus, B.L., Falkenstein, P.L., Miller, R.W., Ning, and H., Altemus, R., 2001. "Remote optical fiber dosimetry," *Nucl. Instrum. Methods. Phys. Res. B* **184**, 55–67.
- IAEA, 2001. *Cytogenetic Analysis for Radiation Dose Assessment: A Manual*. Vienna, Austria: International Atomic Energy Agency.
- IAEA, 2005. *Generic Procedures for Medical Response During a Nuclear or Radiological Emergency*, Vienna, Austria: International Atomic Energy Agency.
- ICRP, 1996b. *Conversion Coefficients for Use in Radiological Protection against External Radiation*, Publication 74. Oxford: Pergamon Press.
- ICRP, 1955. "Recommendations of International Commission on Radiological Protection," *Brit. J. Radiol.* (Suppl. 6).
- ICRP, 1979. *Limits of Intakes of Radionuclides by Workers*. Publication 30, Part 1. Oxford: Pergamon Press.
- ICRP, 1986. *The Metabolism of Plutonium and Related Elements*, Publication 48, Oxford: Pergamon Press.

- ICRP, 1988a. *Limits of Intakes of Radionuclides by Workers*, Publication 30, Part 4, Add., New York: Pergamon Press.
- ICRP, 1980. "Biological effects of inhaled radionuclides," *Ann. ICRP* **31**(1/2), 4.
- ICRP, 1988b. *Individual Monitoring for Intakes of Radionuclides by Workers: Design and Interpretation*, Publication 54. Oxford: Pergamon Press.
- ICRP, 1989. *Age Dependent Doses to Members of the Public from Intake of Radionuclides*, Part 1, Publication 56. Oxford: Pergamon Press.
- ICRP, 1993. *Age Dependent Doses to Members of the Public from Intake of Radionuclides*, Part 2, Publication 67. Oxford: Pergamon Press.
- ICRP, 1994a. *Human Respiratory Tract Model for Radiological Protection*, Publication 66. Oxford: Pergamon Press.
- ICRP, 1994b. *Dose Coefficients for Intakes of Radionuclides by Workers*, Publication 68. Oxford: Pergamon Press.
- ICRP, 1995a. *Age Dependent Doses to Members of the Public from Intake of Radionuclides*, Part 3, Publication 69. Oxford: Pergamon Press.
- ICRP, 1995b. *Age Dependent Doses to Members of the Public from Intake of Radionuclides*, Part 4, Publication 71. Oxford: Pergamon Press.
- ICRP, 1996a. *Age Dependent Doses to Members of the Public from Intake of Radionuclides*, Part 5. *Compilation of Ingestion and Inhalation Dose Coefficients*, Publication 72. Oxford: Pergamon Press.
- ICRP, 1997. *Individual Monitoring for Internal Exposure of Workers: Replacement of ICRP Publication 54*. Publication 78. Oxford: Pergamon Press.
- Ikeya, M., and Ishii, H., 1989. "Atomic bomb and accident dosimetry with ESR: natural rocks and human tooth *in vivo* spectrometer," *Int. J. Rad. Appl. Instrum. A* **40**(10–12), 1021–1027.
- Issaq, H.J., Conrads, T.P., Prieto, D.A., Tirumalai, R., and Veenstra, T.D., 2003. "SELDI-TOF MS for diagnostic proteomics," *Anal. Chem.* **75**, 148A–155A.
- Jain, K.K., 2002. "Proteomics-based anticancer drug discovery and development," *Technol. Cancer Res. Treat.* **1**, 231–236.
- James, S.E., Arlett, C.F., Green, M.H., and Bridges, B.A., 1983. "Radiosensitivity of human T-lymphocytes proliferating in long term culture," *Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med.* **44**, 417–422.
- Jones, I.M., Tucker, J.D., Langlois, R.G., Mendelsohn, M.L., Pleshonov, P., and Nelson, D.O., 2001. "Evaluation of three somatic genetic biomarkers as indicators of low dose radiation effects in clean-up workers of the Chernobyl nuclear reactor accident," *Radiat. Prot. Dosimetry* **97**, 61–67.
- Jones, S.R., 1985. "Derivation and validation of a urinary excretion function for plutonium applicable over tens of years post uptake," *Radiat. Protect. Dosim.* **11**, 19–27.
- Justus, B.L., Rychnovsky, S., Merritt, C.D., Pawlovitch, K.J., and Huston, A.L., 1999. "Optically stimulated luminescence radiation dosimetry using doped silica glass," *Radiat. Prot. Dosim.* **84**, 189–192.
- Kaibao, L., *et al.*, 1986. "Investigations on the TL properties of chemical reagent NaCl," *Radiat. Prot. Dosim.* **17**, 411–414.
- Kanda, R., Minamihisamatsu M., and Hayata, I., 2002. "Dynamic analysis of chromosome aberrations in three victims of the Tokaimura criticality accident," *Int. J. Radiat. Biol.* **78**, 857–862.
- Kanda, R., Hayata, I., and Lloyd, D.C., 1996. "Easy biodosimetry for high-dose radiation exposures using drug-induced, prematurely condensed chromosomes," *Int. J. Radiat. Biol.* **75**, 441–446.
- Kang, C.M., Park, K.P., Song, J.E., Jeoung, D.I., Cho, C.K., Kim, T.H., Bae, S., Lee, S.J., and Lee, Y.S., 2003. "Possible biomarkers for ionizing radiation exposure in human peripheral blood lymphocytes," *Radiat. Res.* **159**, 312–319.
- Karpas Z., Halicz, L., Roiz, J., Marko, R., Karorza, E., Lorber, A., and Goldbart, Z., 1996. "Inductively coupled plasma mass spectrometry as a simple, rapid, inexpensive method for determination of uranium in urine and fresh water; comparison LIF," *Health Phys.* **71**, 6.

- Khalifa, M.S., Al Khalifa, I.J.M., and Durrani, S.A., 1986. "Analysis of thermoluminescence glow curves of minerals sphene and epidote for radiation damage studies," *Rad. Prot. Dosim.* **17**, 407–410.
- Khan, H. M., and Delincée, H., 1995. "Detection of radiation treatment of spices and herbs of Asian origin using thermoluminescence of mineral contaminants," *Appl. Radiat. Isot.* **46**(10), 1071–1075.
- Kharitonov, S.A., and Barnes, P.J., 2001. "Exhaled markers of pulmonary disease," *Am. J. Respir. Crit. Care Med.* **163**, 1693–1722.
- Klein, D.M., Yukihiro, E.G., Bulur, E., Durham, J.S., Akselrod, M.S., and McKeever, S.W.S., 2004. *An Optical Fiber Radiation Sensor for Remote Detection of Radiological Materials*. IEEE.
- Krahenbul, M.P., and Slaughter, D.M., 1998. "Improved methodology for measuring plutonium burden in human urine using fission track," *J. Radioanal. Nucl. Chem.* **230**, 153.
- Krieg, R.C., Fogt, F., Braunschweig, T., Herrmann, P.C., Wollscheidt, V., and Wellmann, A., 2004. "ProteinChip Array analysis of microdissected colorectal carcinoma and associated tumor stroma shows specific protein bands in the 3.4 to 3.6 kDa range," *Anticancer Res.* **24**, 1791–1796.
- Kukar, T., Eckenrode, S., Gu, Y., Lian, W., Megginson, M., She, J.X., and Wu, D., 2002. "Protein microarrays to detect protein–protein interactions using red and green fluorescent proteins," *Anal. Biochem.* **306**, 50–54.
- Kurz, E.U., and Lees-Miller, S.P., 2004. "DNA damage-induced activation of ATM and ATM-dependent signaling pathways," *DNA Repair.* **3**, 889–900.
- Langham, W.H., Bassett, S.H., Harris, P.S., and Carter, R.E., 1980. "Distribution and excretion of plutonium administered intravenously to man," *Health Phys.* **38**, 1031–1060.
- Leggett, R.W., and Eckerman, K.F., 1987. "A method for estimating the systemic burden of Pu from urinalysis," *Health Phys.* **52**, 337–346.
- Leslie, M.D., and Dische, S., 1992. "Changes in serum and salivary amylase during radiotherapy for head and neck-cancer—a comparison of conventionally fractionated radiotherapy with chart," *Radiotherapy Oncology* **24**, 27–31.
- Leggett, R.W., 2001. "Consistent biokinetic models for the actinide elements," *Rad. Prot. Env.* **24**, 616–622.
- Lipshutz, R.J., Fodor, S.P., Gingeras, T.R., and Lockhart, D.J., 1999. "High density synthetic oligonucleotide arrays," *Nature Genetics*, **21**, 20–24.
- Lloyd, D.C., Edwards A.A., Moquet J.E., and Guerreo-Carbajal, Y.C., 2000. "The role of cytogenetics in early triage of radiation casualties," *Appl. Rad. Isot.* **52**, 1107–1112.
- Lockhart, D.J., Dong, H., Byrne, M.C., Follettie, M.T., Gallo, M.V., Chee, M.A., Mittman, M., Wang, C., Kobayashi, M., Horton, H., and Brown, E.L., 1996. "Expression monitoring by hybridization to high-density oligonucleotide arrays," *Nature Biotechnol.* **14**, 1675–1680.
- Lubenau and Strom, 2002. "Safety and security of radiation sources in the aftermath of 11 September 2001," *Health Physics*. **83**, 155–164.
- Lucas, J.A., Straume, T., Poggensee, M., Kodama, Y., Nakano, M., Ohtaki, K., Weier, H.U., Pinkel, D., and Gray, J., 1992. "Rapid translocation frequency analysis in humans decades after exposure to ionizing radiation," *Int. J. Rad. Biol.* **62**, 53–63.
- MacVitte, T.J., Weiss, J.F., and Browne, E.D., Eds., 1996. *Proceedings of Advances in the Treatment of Radiation Injuries*. Tarrytown, NY: Elsevier Sciences.
- McAninch, J.E., and Hamilton, T.F., 1999. *Measurement of Plutonium and Other Actinide Elements at the Center for Accelerator Mass-Spectrometry: A Comparative Assessment of Competing Techniques*. [UCRL-ID-133118]. Lawrence Livermore National Laboratory, Livermore, CA.
- Meek, D.W., 2004. "The p53 response to DNA damage," *DNA Repair.* **3**, 1049–1056.
- Mendelsohn, M.L., Mohr, L.C., and Peeters, J.P., Eds., 1998. *Biomarkers: Medical and Workplace Applications*. Washington, DC: Joseph Henry Press.

- Miller, R.W., 1995. "Delayed effects of external radiation exposure: a brief history," *Radiat. Res.* **144**, 160–169.
- Miyake, M., Liu, K.J., Walczak, T., and Swartz, H.M., 2000. "In vivo EPR dosimetry of accidental exposures to radiation: experimental results indicating the feasibility of practical use in human subjects," *Appl. Radiat. Isot.* **52**, 1031–1038.
- Moore, D.H., Tucker, J.D., Jones, I.M., Langlois, R.G., Pleshano, V. P., Vorobtsova, I., and Jensen, R., 1997. "A study of the effects of exposure on cleanup workers at the Chernobyl nuclear reactor accident using multiple end points," *Radiat. Res.* **148**, 463–475.
- Moskalev, Y. L., Ed., 1974. *Distribution, Biological Effects and Accelerated Excretion of Radioactive Isotopes* [AEC-TR-7590]. Translated from the Russian by the U.S. Atomic Energy Commission. Springfield, VA: National Technical Information Service.
- Mueller, W., Schubert, J., Benzing, A., and Geiger, K., 1998. "Method for analysis of exhaled air by microwave energy desorption coupled with gas chromatography–flame ionization detection–mass spectrometry," *J. Chromatogr. B* **716**, 27–38.
- National Council on Radiation Protection and Measurements, 1980. *Management of Persons Accidentally Contaminated with Radionuclides* [NCRP Report 65]. Bethesda, MD: National Council on Radiation Protection and Measurements.
- Okumura, T., Takasu, N., and Ishimatsu, S., *et al.*, 1996. "Report on 640 victims of the Tokyo subway sarin attack," *Ann. Emerg. Med.* **28**, 129–135.
- Pallotta, N., Tomei, E., Viscido, A., Calabrese, E., Marcheggiano, A., Caprilli, R., and Corazziari, E., 2005. "Small intestine contrast ultrasonography: an alternative to radiology in the assessment of small bowel disease," *Inflamm. Bowel Dis.* **2**, 146–153.
- Park, W.Y., Hwang, C.I., Im, C.N., Kang, M.J., Woo, J.H., Kim, J.H., Kim, Y.S., Kim, H., Kim, K.A., Yu, H.J., Lee, S.J., Lee, Y.S., and Seo, J.S., 2002. "Identification of radiation-specific responses from gene expression profile," *Oncogene* **21**, 8521–8528.
- Peterson, L.E., 2002. "Factor analysis of cluster-specific gene expression levels from cDNA microarrays," *Comput. Meth. Prog. Biomed.* **69**, 179–188.
- Peterson, L.E., 2003. "Partitioning large-scale microarray-based gene expression profiles using principal component analysis," *Comput. Meth. Prog. Biomed.* **70**, 107–119.
- Phillips, G.W., *et al.*, 2004. "Neutron spectrometry using CR-39 track etch detectors," *Proceedings of the 14th International Conference on Solid State Dosimetry*, New Haven CT, June 27–July 2.
- Polf, J.C., Yukihiro, E.G., Akselrod, M.S., and McKeever, S.W.S., 2004. "Real-time luminescence from Al₂O₃ fiber dosimeters," *Radiat. Meas.* **38**, 227–240.
- Prasanna, P.G., Escalada, N.D., and Blakely, W.F., 2000. "Induction of premature chromosome condensation by a phosphatase inhibitor and a protein kinase in unstimulated human peripheral blood lymphocytes: a simple and rapid technique to study chromosome aberrations using specific whole-chromosome DNA hybridization probes for biological dosimetry," *Mutat. Res.* **466**, 131–141.
- Prasanna, P.G., Subramaniam, U. Greenhill G.R., Loats, H., Jacocks, J.M., and Jackson, W.E., and Blakely, W.F., 2003. "Cytogenetic biodosimetry strategy for potential radiation mass casualties," in *The Health Physics Society Midyear Topical Meeting on Homeland Defense and Emergency Response*. Washington, DC: Health Physics Society, 218–223.
- Pyatkin, E.K., Nugis, V.Y., and Chrikov, A.A., 1989. "Absorbed dose estimation according to the results of cytogenetic investigations of lymphocyte cultures of persons who suffered in the accident at Chernobyl atomic power station," *Rad. Med.* **4**, 52.
- Rabbe, O.G., Ed., 1994. *Internal Radiation Dosimetry*. Madison, WI: Medical Physics Publishing. Health Physics Society Summer School.
- Ramalho, A.T., and Nascimento, A.C., 1991. "The fate of chromosomal aberrations in 137 Cs-exposed individuals in the Goiania radiation accident," *Health Phys.* **60**, 67–70.

- Radiation Effects Research Foundation, 1983. *US–Japan Joint Workshop for Reassessment of Atomic Bomb Radiation Dosimetry*, Hiroshima, Japan: Radiation Effects Research Foundation.
- Roswell, R.L., Goans, R.E., and Cantrell, J.H., Jr., 1977. *High Resolution Ultrasonic Scanning of Animal and Human Tissue in vivo* [ORNL/TM 5934], Oak Ridge National Laboratory, Oak Ridge, TN.
- Sankaranarayanan, K., 1998. “Ionizing radiation and genetic risks IX. estimates of the frequencies of Mendelian diseases and spontaneous mutation rates in human populations: a 1998 perspective,” *Mutat. Res.* **41**, 129–78.
- Sasaki, M.S., Hayata, I., Kamada, N., Kodama, N., and Kodama, S., 2000. “Chromosome aberration analysis in persons exposed to low-level radiation from JCO criticality accident in Tokaimura.” *J. Radiat. Res.* **4**, S107–116.
- Sevan'kaev, A.V., 2000. “Results of cytogenetic studies of the consequences of the Chernobyl accident,” *Radiat. Biol. Radioecol.* **40**, 589–595.
- Shigematsu, I., Ito, C., Kamada, M., Akiyama, M., and Sasaki, H., 1995. *Effects of A-Bomb Radiation on the Human Body*. Tokyo, Japan: Hardwood Academic Publishers.
- Sies, H., 1997. “Oxidative stress: oxidants and antioxidants,” *Exp. Physiol.* **82**, 291–295.
- Sine, R.C., Levine, I.H., Jackson, W.E., Hawley, A.L., Prasanna, P.G., and Grace, M.B., *et al.*, 2001. “Biodosimetry Assessment Tool: a post-exposure software application for management of radiation accidents,” *Mil. Med.* **166**, 85–87.
- Sun, C., and Lee, D., 1999. “Plutonium fecal and urinary excretion functions: derivation from a systemic whole-body retention function,” *Health Phys.* **76**, 619–627.
- Swartz, H.M., Walczak, T., and Iwasaki, A., 2004a. “*In Vivo* EPR dosimetry to quantify exposures to clinically significant doses of ionizing radiation,” in *Abstracts, 14th International Conference on Solid State Dosimetry*, New Haven, CT, p. 53.
- Swartz, H.M., Iwasaki, A., Walczak, T., Demidenko, E., Salikhov, I., Lesniewski, P., Starewicz, P., Schauer, D., and Romanyukha, A., 2004b. “Measurements of clinically significant doses of ionizing radiation using non-invasive *in vivo* EPR spectroscopy of teeth *in situ*,” *Appl. Radiat. Isot.* **62**, 293–299.
- Tawn, E.J., Whitehouse, C.A., Daniel, C.P., Tarone, R.E., Bothwell, A.M., and Fisher, A., 2003. “Somatic cell mutations at the glycophorin A locus in erythrocytes of radiation workers from the Sellafield Nuclear Facility,” *Rad. Res.* **159**, 117–122.
- Taylor, D.M., 1995. “Environmental plutonium in humans,” *Appl. Radiat. Isot.* **46**, 1245–1252.
- Thompson, L.H., and Schild, D., 2001. “Homologous recombinational repair of DNA ensures mammalian chromosome stability,” *Mutat. Res.* **477**, 131–153.
- Tirumalai, R.S., Chan, K.C., Prieto, D.A., Issaq, H.J., Conrads, T.P., and Veenstra, T.D., 2003. “Characterization of the low molecular weight human serum proteome,” *Mol. Cell. Proteomics* **2**, 1096–103.
- Tusher, V.G., Tibshirani, R., and Chu, G., 2001. “Significance analysis of microarrays applied to the ionizing radiation response,” *Proc. Nat. Acad. Sci.* **17**, 17.
- UNSCEAR, 1994. *United Nations Scientific Committee on the Effects of Atomic Radiation, Sources and Effects of Ionizing Radiation, Report to the General Assembly, with Scientific Annexes, Adaptive Responses to Radiation of Cells and Organisms*. New York, NY: United Nations, 187–272.

Voisin, P., Benderitter, M., Claraz, M., Chambrette, V., Sorokine-Durm, I., and Delbros, M., *et al.*, 2001. "The cytogenetic dosimetry of recent accidental overexposure," *Cell. Mol. Biol.* **47**, 557–564.

Voisin, P., Barquinero, F., Blakely, B., Lindholm, C., Lloyd, D., and Luccioni, C., *et al.*, 2002. "Towards a standardization of biological dosimetry by cytogenetics," *Cell Mol Biol.* **48**, 501–504.

Walker, R.I., and Cervený, R.J., Eds., 1989. *Medical Consequences of Nuclear Warfare*. Fall Church, VA: Office of the Surgeon General. Available at www.afri.usuhs.mil.

Waselenko, S.K., MacVitte, T.J., Blakely, W.F., Pesek, N., Wiley, A.L., Dickerson, W., Tsu, H., Confer, D., Coleman, N., Seed, T., Lowry, P., Armitage, J., and Daniak, N., (2004). "Medical Management of the Acute Radiation Syndrome: Recommendations of the Strategic National Stockpile Radiation Working Group," *Ann. Int. Med.* **140**, 1087–1051.

Werner, T., 2001. "Cluster analysis and promoter modelling as bioinformatics tools for the identification of target genes from expression array data," *Pharmacogenomics* **2**, 25–36.

Woloschak, G.E., and Paunesku, T., 1997. "Mechanisms of radiation-induced gene response," *Stem Cells*. **15**, 15–25.

Wrenn, M.E., Singh, N.P., and Xue, Y.H., 1994. "Urinary excretion of ²³⁹Pu by the general population: Measurement technique and results," *Radiat. Prot. Dosim.* **53**, 81–84.

Yamanaka, C., Ikeya, M., and Hara, H., 1993. "ESR cavities for *in vivo* dosimetry of tooth enamel," *Appl. Rad. Isot.* **44** (1–2), IN3–IN4.

Yin, E., Nelson, D.O., Coleman, M.A., Peterson, L.E., and Wyrobek, A.J., 2003. "Gene expression changes in mouse brain after exposure to low-dose ionizing radiation," *Int. J. Radiat. Biol.* **79**, 759–75.



Appendix A

Joint Interagency Working Group Participants

William F. Blakely, Ph.D.	Armed Forces Radiobiology Research Institute
Brooke Buddemeier	Department of Homeland Security
Clay Easterly, Ph.D.	Oak Ridge National Laboratory
Christine Hartmann-Siantar, Ph.D.	Lawrence Livermore National Laboratory
David Hoover, M.D.	Department of Homeland Security
Timothy Gondre-Lewis, Ph.D.	National Institute of Allergy and Infectious Diseases/ National Institutes of Health
Michael A. Noska, Ph.D.	Food and Drug Administration
Pataje G.S. Prasanna, Ph.D.	Armed Forces Radiobiology Research Institute
Narayani Ramakrishnan, Ph.D.	National Institute of Allergy and Infectious Diseases/ National Institutes of Health
Steven L. Simon, Ph.D.	National Cancer Institute/National Institutes of Health
James Smith, Ph.D.	Centers for Disease Control and Prevention
Kenneth Turteltaub, Ph.D.	Lawrence Livermore National Laboratory
Albert Wiley, Jr., M.D., Ph.D.	Oak Ridge Institute of Science and Engineering/Radiation Emergency Assistance Center/Training Site



Appendix B

List of Abbreviations

AEC	Atomic Energy Commission
cGy	centi gray, 0.1 gray
COS	Commercial Off-the-Shelf
CPS	Counts Per Second
CW-SOL	Continuous-wave Optically Stimulated Luminescence
DNA	Deoxyribonucleic Acid
EPR/ESR	Electron Paramagnetic Resonance/Electron Spin Resonance
FISH	Fluorescence <i>In Situ</i> Hybridization
Gy	gray
HHA	Handheld Assay
IAEA	International Atomic Energy Agency
IND	Improvised Nuclear Device
ISO	International Organization for Standardization
JIWG	Joint Interagency Working Group
LFD	Lateral Flow Device
LIMS	Laboratory Information Management Systems
mRNA	Messenger Ribonucleic Acid
OSL	Optically Stimulated Luminescence
PCC	Premature Chromosome Condensation
PCR	Polymerase Chain Reaction
POSL	Pulsed Optically Stimulated Luminescence
REAC/TS	Radiation Emergency Assistance Center/Training Site
RDD	Radioactive Dispersal Device
RL	Radio Luminescence
R/N	Radiological and Nuclear
SAGE	Serial Analysis of Gene Expression
SCT	Stem Cell Transplant
SIRAD™	Self-Indicating Instant Radiation Alert Dosimeter
S/N	Signal-To-Noise
TL	Thermo Luminescence

